var title_f30_1_30736="Para Hisian pacing ECG";
var content_f30_1_30736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Para Hisian pacing ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient #6. 12-lead surface electrocardiogram: (A) after atrioventricular node radiofrequency ablation: chronic atrial fibrillation with nodal escape rhythm (QRS 100 ms); (B) during direct His-bundle pacing: paced QRS duration 100 ms, with morphology and electric axis equal to the native QRS; (C) during right apical ventricular pacing: paced QRS duration 160 ms, with extreme left-axis deviation and \"left bundle block\" morphology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Occhetta E, Bortnik M, Magnani A, et al. Prevention of ventricular desynchronization by permanent para-Hisian pacing after atrioventricular node ablation in chronic atrial fibrillation: a crossover, blinded, randomized study versus apical right ventricular pacing. J Am Coll Cardiol 2006; 47:1938. Copyright &copy;2006 American College of Cardiology Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30736=[""].join("\n");
var outline_f30_1_30736=null;
var title_f30_1_30737="Nevus central hypopigmentation";
var content_f30_1_30737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dermoscopic image of a nevus with a peripheral reticular and central hypopigmented pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drs. Ashfaq Marghoob and Natalia Jaimes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30737=[""].join("\n");
var outline_f30_1_30737=null;
var title_f30_1_30738="Patient information: Normal sexual development (puberty) (The Basics)";
var content_f30_1_30738=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"28\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16737\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/43/22194\">",
"          Male reproductive anatomy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/12/1218\">",
"         Patient information: Acne (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/56/14211\">",
"         Patient information: Choosing birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/58/31650\">",
"         Patient information: Early puberty (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/31/13810\">",
"         Patient information: Late puberty (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/21/1363\">",
"         Patient information: Teen sexuality (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?19/40/20099\">",
"         Patient information: Acne (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/8/35973\">",
"         Patient information: Adolescent sexuality (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Normal sexual development (puberty) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/normal-sexual-development-puberty-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H26561245\">",
"      <span class=\"h1\">",
"       What is sexual development?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sexual development is a term for the changes the body goes through during the pre-teen and teen years. Another word for sexual development is &ldquo;puberty.&rdquo;",
"     </p>",
"     <p>",
"      The biggest changes during puberty are that boys&rsquo; and girls&rsquo; bodies:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Grow taller &ndash; Children usually grow a lot in a short amount of time. This is called a &ldquo;growth spurt.&rdquo;",
"       </li>",
"       <li>",
"        Become more like adults&rsquo; bodies &ndash; As a child&rsquo;s body changes to an adult&rsquo;s body, it becomes possible for a girl to get pregnant and for a boy to get a girl pregnant.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26561260\">",
"      <span class=\"h1\">",
"       What causes puberty?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Puberty is caused by hormones in the body. These hormones come from the brain as well as organs called the ovaries (in girls) and the testicles (in boys) (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"mobipreview.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef68075 \" href=\"mobipreview.htm?21/43/22194\">",
"       figure 2",
"      </a>",
"      ). The ovaries make a hormone called &ldquo;estrogen.&rdquo; The testicles make a hormone called &ldquo;testosterone.&rdquo; Estrogen and testosterone cause many of the changes in the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26561275\">",
"      <span class=\"h1\">",
"       When does puberty usually start?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Puberty starts at different times in different children. Girls usually start puberty between ages 9 and 12. Boys usually start puberty between ages 10 and 13. But it can be normal for children to start puberty before or after these ages. The exact time a child starts puberty depends on different factors, including his or her genes, nutrition, and weight.",
"     </p>",
"     <p>",
"      It&rsquo;s helpful to talk to your child before puberty starts. Let him or her know what body changes to expect and that these changes are normal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26561290\">",
"      <span class=\"h1\">",
"       What changes happen in girls?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The changes that happen during puberty in girls are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The breasts grow bigger. In many girls, this is the first sign of puberty.",
"       </li>",
"       <li>",
"        Hair grows in the genital area (pubic hair), under the arms, and on the legs. In some girls, pubic hair is the first sign of puberty.",
"       </li>",
"       <li>",
"        Girls start to get their monthly periods. Monthly periods usually start within 2 years after the breasts or pubic hair start growing. When a girl first starts getting her period, she might not get one every month. It is normal for a period to skip a month, or come 2 times in 1 month. Some girls feel bloated or have mood changes right before they get their period.",
"       </li>",
"       <li>",
"        Girls can have white or clear vaginal discharge. Vaginal discharge is the term doctors use to describe the small amount of fluid that comes out of the vagina.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26561305\">",
"      <span class=\"h1\">",
"       What changes happen in boys?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The changes that happen during puberty in boys are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The testicles get bigger. This is usually the first change that happens.",
"       </li>",
"       <li>",
"        The penis gets longer and wider.",
"       </li>",
"       <li>",
"        Hair grows in the genital area (pubic hair), on the face, and under the arms.",
"       </li>",
"       <li>",
"        The voice changes.",
"       </li>",
"       <li>",
"        Boys can ejaculate a small amount of sperm at night while they sleep. This is sometimes called a &ldquo;wet dream.&rdquo;",
"       </li>",
"       <li>",
"        The breasts can get slightly bigger. This usually goes away over time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26561320\">",
"      <span class=\"h1\">",
"       What other changes can happen during puberty?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Other changes that can happen are listed below. These things are all normal, but some can be bothersome or embarrassing to your child. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pimples (acne) &ndash; To help prevent pimples, your child can wash his or her face twice a day with a gentle non-soap facial skin cleanser. You can also ask your child&rsquo;s doctor or nurse for advice on how to treat pimples.",
"       </li>",
"       <li>",
"        Sweating under the armpits and body odor &ndash; Puberty is the time that most children start using an anti-perspirant or deodorant.",
"       </li>",
"       <li>",
"        Eyesight changes &ndash; Children who wear glasses usually start needing them during puberty.",
"       </li>",
"       <li>",
"        Mood changes or mood swings",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      During puberty, many teens start having sexual feelings and might start having sex. But even though their bodies look grown up, their thoughts and feelings are not always grown up. Because of this, many teens don&rsquo;t use protection. This can lead to pregnancy or getting an infection from sex.",
"     </p>",
"     <p>",
"      Talk to your teen about how to avoid pregnancy or infections from sex. The only sure way to prevent these things is not to have sex. If teens do have sex, they can lower their chance of an unplanned pregnancy by using birth control. But some types of birth control do not protect against infections from sex. To lower the chance of getting an infection, teens should use a condom every time they have sex.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26561334\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/58/31650?source=see_link\">",
"       Patient information: Early puberty (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/31/13810?source=see_link\">",
"       Patient information: Late puberty (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/21/1363?source=see_link\">",
"       Patient information: Teen sexuality (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/12/1218?source=see_link\">",
"       Patient information: Acne (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/56/14211?source=see_link\">",
"       Patient information: Choosing birth control (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/8/35973?source=see_link\">",
"       Patient information: Adolescent sexuality (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/40/20099?source=see_link\">",
"       Patient information: Acne (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/1/30738?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16737 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30738=[""].join("\n");
var outline_f30_1_30738=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26561245\">",
"      What is sexual development?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26561260\">",
"      What causes puberty?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26561275\">",
"      When does puberty usually start?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26561290\">",
"      What changes happen in girls?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26561305\">",
"      What changes happen in boys?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26561320\">",
"      What other changes can happen during puberty?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26561334\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16737\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/43/22194\">",
"       Male reproductive anatomy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/40/20099?source=related_link\">",
"      Patient information: Acne (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/12/1218?source=related_link\">",
"      Patient information: Acne (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/8/35973?source=related_link\">",
"      Patient information: Adolescent sexuality (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/58/31650?source=related_link\">",
"      Patient information: Early puberty (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/31/13810?source=related_link\">",
"      Patient information: Late puberty (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/21/1363?source=related_link\">",
"      Patient information: Teen sexuality (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_1_30739="Erythrodermic sarcoidosis - chest";
var content_f30_1_30739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythrodermic sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythrodermic sarcoidosis. This patient has large, geometric, erythematous plaques covering most of the body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc. Original photo provided by NYU (Tisch) Department of Dermatology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30739=[""].join("\n");
var outline_f30_1_30739=null;
var title_f30_1_30740="Ivacaftor: Patient drug information";
var content_f30_1_30740=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ivacaftor: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/58/22437?source=see_link\">",
"     see \"Ivacaftor: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/43/8885?source=see_link\">",
"     see \"Ivacaftor: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13764717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kalydeco&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15801070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kalydeco&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13768871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13768872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3638861",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used treat cystic fibrosis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13768838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3638849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ivacaftor or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13768840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697801",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3638867",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid Seville oranges.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13768875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13768841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13768874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3638851",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with fatty foods like eggs, butter, peanut butter, or cheese pizza.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13768839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13768876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13768842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83368 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-DD2D800F1C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30740=[""].join("\n");
var outline_f30_1_30740=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13764717\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15801070\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768871\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768872\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768838\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768840\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768875\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768841\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768874\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768839\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768876\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13768842\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/58/22437?source=related_link\">",
"      Ivacaftor: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/43/8885?source=related_link\">",
"      Ivacaftor: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_1_30741="Asenapine: Patient drug information";
var content_f30_1_30741=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Asenapine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/56/2951?source=see_link\">",
"     see \"Asenapine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8061396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Saphris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14942057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Saphris&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10031331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10031333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia. It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat manic low mood (depression).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10031332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to asenapine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10031337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a family history of high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697268",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol or triglyceride levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are overweight, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10031338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10031340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, period changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10031335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695688",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sublingual tablet: Place under your tongue and let melt.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694755",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not chew or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696381",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat or drink for at least 10 minutes after taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10031336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10031341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10031342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10787 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30741=[""].join("\n");
var outline_f30_1_30741=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8061396\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14942057\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031331\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031333\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031332\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031337\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031338\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031340\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031335\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031336\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031341\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031342\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/56/2951?source=related_link\">",
"      Asenapine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_1_30742="Nabothian cyst";
var content_f30_1_30742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73788%7EOBGYN%2F53598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73788%7EOBGYN%2F53598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colposcopic view of a Nabothian cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cyst (the raised area between lines A+B) has a yellow hue and is covered by enlarged capillaries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kathryn F McGonigle, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Nabothian cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Marc Steben, MD, Institut National de Sant&eacute; Publique du Qu&eacute;bec.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30742=[""].join("\n");
var outline_f30_1_30742=null;
var title_f30_1_30743="Acetaminophen, aspirin, and caffeine: Drug information";
var content_f30_1_30743=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen, aspirin, and caffeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/23/373?source=see_link\">",
"    see \"Acetaminophen, aspirin, and caffeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anacin&reg; Advanced Headache Formula [OTC];",
"     </li>",
"     <li>",
"      Excedrin&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Excedrin&reg; Migraine [OTC];",
"     </li>",
"     <li>",
"      Fem-Prin&reg; [OTC];",
"     </li>",
"     <li>",
"      Goody's&reg; Extra Strength Headache Powder [OTC];",
"     </li>",
"     <li>",
"      Goody's&reg; Extra Strength Pain Relief [OTC];",
"     </li>",
"     <li>",
"      Pain-Off [OTC];",
"     </li>",
"     <li>",
"      Vanquish&reg; Extra Strength Pain Reliever [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pain management:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Based on",
"     <b>",
"      acetaminophen",
"     </b>",
"     component:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate pain: Oral: 325-650 mg every 4-6 hours as needed; do",
"     <b>",
"      not",
"     </b>",
"     exceed 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate pain associated with migraine headache: Oral: 500 mg/dose (in combination with 500 mg aspirin and 130 mg caffeine) every 6 hours while symptoms persist; do not use for longer than 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Based on",
"     <b>",
"      aspirin",
"     </b>",
"     component:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate pain: Oral: 325-650 mg every 4-6 hours as needed; do",
"     <b>",
"      not",
"     </b>",
"     exceed 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate pain associated with migraine headache: Oral: 500 mg/dose (in combination with 500 mg acetaminophen and 130 mg caffeine) every 6 hours; do not use for longer than 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Product labeling:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excedrin&reg; Extra Strength, Excedrin&reg; Migraine: Oral: 2 doses every 6 hours (maximum: 8 doses/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When used for migraine, do not use for longer than 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Goody's&reg; Extra Strength Headache Powder: Oral: 1 powder, placed on tongue or dissolved in water, every 4-6 hours (maximum: 4 powders/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Goody's&reg; Extra Strength Pain Relief Tablets: Oral: 2 tablets every 4-6 hours (maximum: 8 tablets/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vanquish&reg; Extra Strength Pain Reliever: Oral: 2 tablets every 4 hours (maximum: 12 tablets/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2525227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Product labeling:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excedrin&reg; Extra Strength, Excedrin&reg; Migraine: Oral: Children &gt;12 years: Refer to adult dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Goody's&reg; Extra Strength Headache Powder: Oral: Children &gt;12 years: Refer to adult dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Goody's&reg; Extra Strength Pain Relief Tablets: Oral: Children &gt;12 years: Refer to adult dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vanquish&reg; Extra Strength Pain Reliever: Oral: Children &gt;12 years: Refer to adult dosing",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F129401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Limited, low-dose therapy usually well tolerated in hepatic disease/cirrhosis. However, cases of hepatotoxicity at daily acetaminophen dosages &lt;4 g/day have been reported. Avoid chronic use in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excedrin&reg; Extra Strength, Excedrin&reg; Migraine: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vanquish&reg; Extra Strength Pain Reliever: Acetaminophen 194 mg, aspirin 227 mg, and caffeine 33 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Geltab (Excedrin&reg; Extra Strength, Excedrin&reg; Migraine): Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder (Goody's&reg; Extra Strength Headache Powder): Acetaminophen 260 mg, aspirin 520 mg, and caffeine 32.5 mg [contains lactose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anacin&reg; Advanced Headache Formula: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excedrin&reg; Extra Strength, Excedrin&reg; Migraine, Pain-Off: Acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fem-Prin&reg;: Acetaminophen 194.4 mg, aspirin 226.8 mg, and caffeine 32.4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Goody's&reg; Extra Strength Pain Relief: Acetaminophen 130 mg, aspirin 260 mg, and caffeine 16.25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of mild-to-moderate pain; mild-to-moderate pain associated with migraine headache",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Excedrin&reg; may be confused with Dexedrine&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2525224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetaminophen, aspirin, salicylates, caffeine, or any component of the formulation; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Salicylates may diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Caffeine may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alendronate: Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically gastrointestinal adverse events.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the anticoagulant effect of Salicylates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Salicylates may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Salicylates may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received  platelet inhibitors including aspirin (over 650 mg daily within 1 week). Monitor for bleeding and stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Caffeine may enhance the adverse/toxic effect of Formoterol. Caffeine may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: Aspirin may enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Salicylates may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Caffeine may enhance the adverse/toxic effect of Indacaterol. Caffeine may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, aspirin may decrease absorption of ascorbic acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Aspirin may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).  Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Acid Phosphate: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: Salicylates may diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the metabolism of Caffeine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Levofloxacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Ofloxacin (Systemic); Sparfloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Caffeine may diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of other Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May decrease the serum concentration of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in patients receiving daily aspirin doses greater than 100-150 mg daily.  Management: Avoid daily aspirin doses greater than 100 mg in patients receiving ticagrelor.  Canadian recommendations are to avoid daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiludronate: Aspirin may decrease the serum concentration of Tiludronate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Salicylates may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F129397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Excessive intake of ethanol may increase the risk of acetaminophen-induced hepatotoxicity. Avoid ethanol or limit to &lt;3 drinks/day.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Goodys Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     520-260-32.5 mg (6): $1.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bayer Migraine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-250-65 mg (50): $5.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Excedrin Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-250-65 mg (100): $9.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Excedrin Menstrual Complete Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-250-65 mg (20): $4.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Excedrin Migraine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-250-65 mg (50): $5.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Goodys Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     260-130-16.25 mg (60): $3.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pamprin Max Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250-250-65 mg (24): $4.52",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aqudol (EC);",
"     </li>",
"     <li>",
"      Bufferin Advance (TW);",
"     </li>",
"     <li>",
"      Excedrin (CO);",
"     </li>",
"     <li>",
"      Exidol (IL);",
"     </li>",
"     <li>",
"      Nogren (ID)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F129394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al,  &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cryer B, Verlin RG, Cooper SA, et al, &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Ibuprofen Effects on Thromboxane B2 Concentrations in Aspirin-Treated Healthy Adult Volunteers,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2005, 27(2):185-191.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/15811481/pubmed\" id=\"15811481\" target=\"_blank\">",
"        15811481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Desjardins PJ, Cooper SA, Gallegos TL, et al, &ldquo;The Relative Analgesic Efficacy of Propiram Fumarate, Codeine Aspirin, and Placebo in Postimpaction Dental Pain,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1984, 24(1):35-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/6368614/pubmed\" id=\"6368614\" target=\"_blank\">",
"        6368614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, Campbell RA, Cooper SA, et al, &ldquo;Suppression of Postoperative Pain by Preoperative Administration of Ibuprofen in Comparison to Placebo, Acetaminophen, and Acetaminophen Plus Codeine,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1983, 23(1):37-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/6341415/pubmed\" id=\"6341415\" target=\"_blank\">",
"        6341415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forbes JA, Butterworth GA, Burchfield WH, et al, &ldquo;Evaluation of Ketorolac, Aspirin, and an Acetaminophen-Codeine Combination in Postoperative Oral Surgery Pain,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1990, 10(6 Pt 2):77S-93S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/2082317/pubmed\" id=\"2082317\" target=\"_blank\">",
"        2082317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forbes JA, Keller CK, Smith JW, et al, &ldquo;Analgesic Effect of Naproxen Sodium, Codeine, a Naproxen-Codeine Combination and Aspirin on the Postoperative Pain of Oral Surgery,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1986, 6(5):211-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/3540871/pubmed\" id=\"3540871\" target=\"_blank\">",
"        3540871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Licht H, Seeff LB, and Zimmerman HJ, &ldquo;Apparent Potentiation of Acetaminophen Hepatotoxicity by Alcohol,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1980, 92(4):511.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, \"Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),\"",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, \"The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,\"",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/1/30743/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9192 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-211.167.112.17-380DEE3FB3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30743=[""].join("\n");
var outline_f30_1_30743=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129398\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129408\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129399\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525227\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129400\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129401\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129391\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129382\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129392\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129413\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129406\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525224\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129404\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129388\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129397\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287162\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287164\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322957\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961915\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129394\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9192\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9192|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/23/373?source=related_link\">",
"      Acetaminophen, aspirin, and caffeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_1_30744="Causes of peripheral lymphadenopathy in children";
var content_f30_1_30744=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of peripheral lymphadenopathy in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/1/30744/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30744/contributors\">",
"     Kenneth L McClain, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30744/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/1/30744/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30744/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30744/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30744/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/1/30744/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30744/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/1/30744/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of peripheral lymphadenopathy in children will be reviewed here. The approach to the child with peripheral lymphadenopathy, cervical lymphadenitis, and the causes and evaluation of peripheral lymphadenopathy in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8632?source=see_link\">",
"     \"Etiology and clinical manifestations of cervical lymphadenitis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=see_link\">",
"     \"Approach to the child with peripheral lymphadenopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39080?source=see_link\">",
"     \"Evaluation of peripheral lymphadenopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of peripheral lymph node groups is shown schematically in the Figures (",
"    <a class=\"graphic graphic_figure graphicRef69528 \" href=\"mobipreview.htm?18/53/19285\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57451 \" href=\"mobipreview.htm?2/27/2482\">",
"     figure 2",
"    </a>",
"    ). Normal lymph nodes in most regions usually are less than 1 cm in their longest diameter; normal lymph nodes in the epitrochlear region usually are less than 0.5 cm in diameter, and normal lymph nodes in the inguinal region usually are less than 1.5 cm in diameter. Normal lymph nodes tend to be larger in childhood (ages 2 to 10 years) than later in life. Lymph nodes often are palpable in the inguinal region in healthy individuals, perhaps because chronic trauma and infection are so common in the lower extremities. Lymph nodes also may be palpable in the neck (particularly submandibular lymph nodes) because of previous head and neck infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph node enlargement may be caused by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Replication of cells within the node in response to antigenic stimuli or as a result of malignant transformation",
"     </li>",
"     <li>",
"      Entry of large numbers of cells exogenous to the node (eg, neutrophils or metastatic neoplastic cells)",
"     </li>",
"     <li>",
"      Deposition of foreign material within histiocytic cells of the node (as occurs in lipid storage diseases)",
"     </li>",
"     <li>",
"      Vascular engorgement and edema secondary to local cytokine release",
"     </li>",
"     <li>",
"      Suppuration secondary to tissue necrosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children frequently have palpable lymph nodes because their immune systems are being activated by environmental antigens and the common organisms to which they are exposed. The prevalence of lymphadenopathy in the various lymph node groups varies with age and site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Small occipital and postauricular nodes, for example, are common in infants, but not in older children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/2\">",
"     2",
"    </a>",
"    ]. In contrast, cervical and inguinal nodes are more common after two years of age than in the first six months of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Epitrochlear and supraclavicular adenopathy are uncommon at any age.",
"   </p>",
"   <p>",
"    In one review, 44 percent of children younger than five years who were seen for well-child visits and 64 percent of those seen for \"sick\" visits had lymphadenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/2\">",
"     2",
"    </a>",
"    ]. Most of the children with adenopathy detected at \"sick\" visits were between three and five years of age.",
"   </p>",
"   <p>",
"    Many patients with unexplained lymphadenopathy (and their clinicians) are concerned about the possibility of malignancy. The prevalence of malignancy among patients seen in the primary care setting is relatively low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In contrast, the prevalence of malignancy in lymph node biopsies performed in pediatric referral centers ranges from 13 to 27 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest of these series, 239 children underwent peripheral lymph node biopsies for evaluation of lymphadenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/3\">",
"     3",
"    </a>",
"    ]. The following etiologies were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reactive hyperplasia of undetermined etiology &ndash; 52 percent",
"     </li>",
"     <li>",
"      Granulomatous disease (eg, cat scratch disease, atypical mycobacteria, mycobacterium tuberculosis, fungal infections, or Langerhans cell histiocytosis [histiocytosis X]) &ndash; 32 percent",
"     </li>",
"     <li>",
"      Neoplastic disease &ndash; 13 percent; among these two-thirds had Hodgkin disease",
"     </li>",
"     <li>",
"      Chronic dermatopathic or bacterial infections &ndash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A higher incidence of cancer is expected in patients with certain clinical characteristics, including weight loss (&gt;10 percent of body weight), abnormal complete blood count (CBC) or chest radiograph, generalized adenopathy without a clear etiology, fevers, and lack of upper respiratory tract infection symptoms. We recommend immediate biopsy for patients who have these findings. In conjunction with the other reasons for biopsy (weight loss, abnormal CBC, etc), lymph node biopsy also may be indicated in children with persistently elevated erythrocyte sedimentation rate (ESR) or rising ESR despite antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the child with peripheral lymphadenopathy\", section on 'Lymph node biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphadenopathy can be caused by a vast array of diseases (",
"    <a class=\"graphic graphic_table graphicRef77382 \" href=\"mobipreview.htm?24/2/24620\">",
"     table 1",
"    </a>",
"    ) and drugs (",
"    <a class=\"graphic graphic_table graphicRef61046 \" href=\"mobipreview.htm?7/17/7451\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Some presentations suggest a specific disease process, whereas a few diseases present predominantly with lymphadenopathy.",
"   </p>",
"   <p>",
"    It is clinically useful to classify the causes of lymphadenopathy according to whether the lymphadenopathy is localized (in only one region, such as the neck or axilla) (",
"    <a class=\"graphic graphic_table graphicRef71073 \" href=\"mobipreview.htm?14/41/15005\">",
"     table 3",
"    </a>",
"    ) or generalized (occurring in more than one noncontiguous region) (",
"    <a class=\"graphic graphic_table graphicRef81033 graphicRef66847 \" href=\"mobipreview.htm?30/38/31342\">",
"     table 4A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conditions that can mimic lymphadenopathy are discussed below. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Mimics of lymphadenopathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LOCALIZED LYMPHADENOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized lymphadenopathy is present in only one region, such as the neck or axilla. Unexplained localized (nonsupraclavicular) lymphadenopathy in children without other symptoms usually can be safely managed by two to three weeks of observation as long as the children return for follow-up. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=see_link&amp;anchor=H20#H20\">",
"     \"Approach to the child with peripheral lymphadenopathy\", section on 'Localized nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cervical",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior cervical lymph nodes are enlarged in a variety of infections of the head and neck and in systemic infections such as toxoplasmosis, Epstein-Barr virus, or cytomegalovirus infection. Only one-quarter of patients with enlarged cervical nodes have another serious disease, which most often is mycobacterial. Upper posterior cervical lymphadenopathy rarely is associated with significant diseases in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In considering the causes of cervical lymphadenopathy, it is helpful to distinguish between acute (develops over a few days) and",
"    <span class=\"nowrap\">",
"     subacute/chronic",
"    </span>",
"    (develops over weeks to months) lymphadenopathy and whether the adenopathy is unilateral or bilateral. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8632?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology and clinical manifestations of cervical lymphadenitis in children\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inflamed cervical nodes that develop over a few days and progress to fluctuation, especially in children, typically are caused by staphylococcal (",
"    <a class=\"graphic graphic_picture graphicRef74121 \" href=\"mobipreview.htm?18/6/18542\">",
"     picture 1",
"    </a>",
"    ) and streptococcal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/10\">",
"     10",
"    </a>",
"    ]. The source of infection may be unapparent even after careful examination. Treatment typically begins first with a course of antibiotics, but incision and drainage may be indicated. Antimicrobial treatment of cervical lymphadenitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24857?source=see_link&amp;anchor=H16#H16\">",
"     \"Diagnostic approach to and initial treatment of cervical lymphadenitis in children\", section on 'Initial treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluctuant cervical nodes that develop over weeks to months without significant inflammation or tenderness suggest infection with",
"    <em>",
"     Mycobacterium tuberculosis",
"    </em>",
"    , atypical mycobacteria, or",
"    <em>",
"     Bartonella henselae",
"    </em>",
"    , the agent of cat scratch disease. Cat scratch disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23289?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mycobacterial infections can present with lymphadenopathy alone, especially in the neck (scrofula).",
"    <em>",
"     M. avium",
"    </em>",
"    complex and",
"    <em>",
"     M. scrofulaceum",
"    </em>",
"    account for most cases in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Nodes typically are nontender, enlarge over weeks to months without prominent systemic symptoms, and can progress to matting and fluctuation (",
"    <a class=\"graphic graphic_picture graphicRef69475 \" href=\"mobipreview.htm?40/60/41934\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13994?source=see_link&amp;anchor=H2272512912#H2272512912\">",
"     \"Overview of nontuberculous mycobacterial lymphadenitis in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hard nodes, often associated with cancer in adults, are found infrequently in children. The nodes involved with Hodgkin disease are rubbery and difficult to differentiate from hyperplastic nodes or nodes caused by granulomatous disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32874?source=see_link\">",
"     \"Overview of Hodgkin lymphoma in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less common causes of cervical adenopathy, which are discussed below, include malignancy, Kawasaki disease, Langerhans cell histiocytosis, autoimmune lymphoproliferative disease, Rosai-Dorfman disease, sarcoidosis, and Kikuchi disease. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Uncommon but important causes'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30279?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Supraclavicular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supraclavicular (or lower cervical) (",
"    <a class=\"graphic graphic_figure graphicRef69528 \" href=\"mobipreview.htm?18/53/19285\">",
"     figure 1",
"    </a>",
"    ) lymphadenopathy is associated with a high risk of malignancy (up to 75 percent) in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Right supraclavicular adenopathy is associated with cancer of the mediastinal lymph nodes. Left supraclavicular adenopathy (\"Virchow's node\") suggests intraabdominal malignancy, most often lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Axillary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The axillary nodes receive drainage from the arm, thoracic wall, and breast. Infections, including cat scratch disease, are common causes of axillary lymphadenopathy. In one series of 31 children who underwent axillary node biopsies, 11 (35 percent) had reactive hyperplasia, and five (16 percent) had cat scratch disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23289?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inguinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inguinal lymphadenopathy in children usually is not associated with a specific etiology unless the nodes are very large (&gt;3 cm).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Epitrochlear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpable epitrochlear nodes (",
"    <a class=\"graphic graphic_figure graphicRef57451 \" href=\"mobipreview.htm?2/27/2482\">",
"     figure 2",
"    </a>",
"    ) are often pathologic in children. However, many biopsied nodes show only hyperplasia if they are associated with cuts or abrasions and there are no other signs suggestive of malignancy. The differential diagnosis for epitrochlear lymphadenopathy includes infections of the forearm or hand, leukemia, lymphoma, and atypical mycobacterial infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=see_link\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GENERALIZED LYMPHADENOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized lymphadenopathy is present in two or more noncontiguous regions. It may be a feature of numerous systemic diseases, many of which are recognized by other clinical findings (",
"    <a class=\"graphic graphic_table graphicRef81033 graphicRef66847 \" href=\"mobipreview.htm?30/38/31342\">",
"     table 4A-B",
"    </a>",
"    ). Several of these diseases are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic bacterial or viral illnesses are the most common causes of generalized adenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/12\">",
"     12",
"    </a>",
"    ]. Common viral causes of generalized lymphadenopathy include Epstein-Barr virus or cytomegalovirus mononucleosis, rubella, and measles (in parts of the world where rubella and measles are endemic).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Mononucleosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic infectious mononucleosis is characterized by the triad of moderate to high fever, pharyngitis, and lymphadenopathy. A characteristic distribution of lymph node involvement occurs; typically it is symmetric and involves the posterior cervical more than the anterior cervical chain. The posterior cervical nodes are deep to the sternocleidomastoid muscles (",
"    <a class=\"graphic graphic_figure graphicRef69528 \" href=\"mobipreview.htm?18/53/19285\">",
"     figure 1",
"    </a>",
"    ). Lymphadenopathy also may be present in the axillary and inguinal areas, which helps to distinguish infectious mononucleosis from other causes of pharyngitis. The lymph nodes are kidney-shaped and may be large. Lymphadenopathy peaks in the first week and then gradually subsides over two to three weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphadenopathy is common in primary human immunodeficiency virus (HIV) infection. Nontender adenopathy primarily involving the axillary, cervical, and occipital nodes develops in the majority of individuals during the second week of acute symptomatic HIV infection, concomitant with the emergence of a specific immune response to HIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/12\">",
"     12",
"    </a>",
"    ]. The nodes decrease in size after the acute presentation, but a modest degree of adenopathy tends to persist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3130?source=see_link&amp;anchor=H18840505#H18840505\">",
"     \"Natural history and classification of pediatric HIV infection\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Miliary tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miliary tuberculosis is an important consideration in patients with generalized lymphadenopathy. Miliary tuberculosis can be mistaken for malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/22/34150?source=see_link\">",
"     \"Epidemiology and pathology of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Systemic lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enlargement of lymph nodes occurs in approximately 50 percent of patients with systemic lupus erythematosus (SLE). The nodes typically are soft; nontender; discrete; varying in size from 0.5 to several centimeters; and usually detected in the cervical, axillary, and inguinal areas. Lymphadenopathy is noted more frequently at the onset of disease or in association with an exacerbation. Lymph node enlargement also can be caused by infection or a lymphoproliferative disease in SLE; when infections are present, the enlarged nodes are more likely to be tender. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27303?source=see_link\">",
"     \"Hematologic problems in children and adolescents with systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous medications may cause serum sickness that is characterized by fever, arthralgias, rash, and generalized lymphadenopathy (",
"    <a class=\"graphic graphic_table graphicRef71073 \" href=\"mobipreview.htm?14/41/15005\">",
"     table 3",
"    </a>",
"    ).",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     Phenytoin",
"    </a>",
"    can cause generalized lymphadenopathy in the absence of a serum sickness reaction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Phenytoin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link&amp;anchor=H10#H10\">",
"     \"Drug eruptions\", section on 'Hypersensitivity syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     UNCOMMON BUT IMPORTANT CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphadenopathy is a central feature of numerous less common systemic diseases that are important to consider because they are life-threatening or require specific treatment (",
"    <a class=\"graphic graphic_table graphicRef77382 \" href=\"mobipreview.htm?24/2/24620\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoplastic causes of lymphadenopathy include Hodgkin disease, non-Hodgkin lymphoma, neuroblastoma, acute lymphocytic leukemia, acute myeloid leukemia, and rhabdomyosarcoma.",
"   </p>",
"   <p>",
"    The prevalence of malignancy among patients seen in the primary care setting is relatively low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In contrast, the prevalence of malignancy in lymph node biopsies performed in pediatric referral centers ranges from 13 to 27 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As discriminant features of malignancy versus other etiologies, fever, duration of adenopathy, and tenderness are not particularly helpful.",
"   </p>",
"   <p>",
"    However, a higher incidence of cancer is expected in patients with certain clinical characteristics, including weight loss (&gt;10 percent of body weight), abnormal complete blood count (CBC) or chest radiograph, generalized adenopathy without a clear etiology, fevers, and lack of upper respiratory tract infection symptoms. We recommend immediate biopsy for patients who have these findings. In conjunction with the other reasons for biopsy (weight loss, abnormal CBC, etc), lymph node biopsy also may be indicated in children with persistently elevated erythrocyte sedimentation rate (ESR) or rising ESR despite antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the child with peripheral lymphadenopathy\", section on 'Lymph node biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Kawasaki disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease, though an uncommon illness, is the most frequent cause of childhood vasculitis. This syndrome is associated with fever, cervical lymphadenopathy, and a variety of other manifestations, including conjunctivitis, mucositis, rash, and coronary artery aneurysms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Tularemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with tularemia typically present with fever and a single erythematous papulo-ulcerative lesion with a central eschar (",
"    <a class=\"graphic graphic_picture graphicRef51005 \" href=\"mobipreview.htm?25/51/26418\">",
"     picture 3",
"    </a>",
"    ) that is accompanied by tender regional lymphadenopathy (",
"    <a class=\"graphic graphic_picture graphicRef52036 \" href=\"mobipreview.htm?5/19/5439\">",
"     picture 4",
"    </a>",
"    ). The majority of cases in the United States occur in Arkansas, Missouri, and Oklahoma. Sources of infections in humans include vectors (eg, ticks, biting flies, and mosquitoes), handling of infected animals (rodents and rabbits), ingestion of inadequately cooked meat, drinking contaminated water, cat scratches or bites, or splashing infected material into the eye or rubbing eyes with contaminated fingers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14166?source=see_link\">",
"     \"Epidemiology, microbiology, and pathogenesis of tularemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30888?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Langerhans cell histiocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Langerhans cell histiocytosis may present with unilateral or bilateral cervical lymph nodes. Sometimes there is massive enlargement similar to those seen in Rosai-Dorfman disease. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Rosai-Dorfman disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hemophagocytic lymphohistiocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophagocytic lymphohistiocytosis patients have diffuse adenopathy in one-third of cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Chronic granulomatous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic granulomatous disease encompasses a heterogeneous group of disorders characterized by genetic defects in the ability of phagocytes to generate reactive oxygen intermediates from molecular oxygen. These defects manifest primarily as an immunodeficiency resulting in frequent, severe infections, including pneumonia, abscesses, suppurative adenitis, osteomyelitis,",
"    <span class=\"nowrap\">",
"     bacteremia/fungemia,",
"    </span>",
"    and superficial skin infections",
"    <span class=\"nowrap\">",
"     (cellulitis/impetigo).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Castleman's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Castleman's disease is an uncommon lymphoproliferative disorder characterized by massive lymphadenopathy and systemic features such as fever, hepatomegaly, splenomegaly, and polyclonal hypergammaglobulinemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/51/6970?source=see_link\">",
"     \"Castleman's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Autoimmune lymphoproliferative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with autoimmune lymphoproliferative disease (ALPS), also known as the Canale-Smith syndrome or",
"    <span class=\"nowrap\">",
"     autoimmunity/lymphoproliferation",
"    </span>",
"    syndrome, usually present in the first year of life with massive cervical adenopathy that may obscure the angle of the jaw [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/13\">",
"     13",
"    </a>",
"    ]. Splenomegaly also can occur. Frequent associations with autoimmune diseases, including hemolytic anemia, neutropenia, immune thrombocytopenia (ITP), glomerulonephritis, and Guillain-Barr&eacute; syndrome, have been reported. The syndrome appears to be caused by a defect in lymphocyte apoptosis (programmed cell death). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/58/30629?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30279?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/246?source=see_link\">",
"     \"Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Rosai-Dorfman disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy) often presents in children with markedly enlarged, nontender cervical adenopathy of massive proportions, similar to patients with ALPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. However, other nodal sites, including the mediastinum, retroperitoneal, axillary, and inguinal sites, also may be involved. Other manifestations include involvement of the nasal cavity, salivary gland tissue and other regions of the head and neck, lytic bone lesions, pulmonary nodules, or rash [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/19\">",
"     19",
"    </a>",
"    ]. Patients often are febrile when massive lymphadenopathy is present. Laboratory evaluations show leukocytosis, polyclonal hypergammaglobulinemia, a hypochromic or normocytic anemia, and elevated ESR. Treatment is uncertain; spontaneous resolution is frequently observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Kikuchi disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kikuchi disease is a rare, benign condition of unknown cause usually characterized by cervical lymphadenopathy (although it may be more generalized) and fever. It is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28647?source=see_link\">",
"     \"Kikuchi's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Inflammatory pseudotumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory pseudotumor of lymph nodes is a syndrome of lymphadenopathy in one or more node groups, often with systemic symptoms. Nodes show a fibrosing and inflammatory process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Churg-Strauss syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive lymphadenopathy in children with asthma may be a rare manifestation of the Churg-Strauss syndrome (asthma, tissue and peripheral blood eosinophilia, and granulomatous vasculitis). A case report of a boy with this triad plus a mediastinal mass suggesting Hodgkin disease has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with sarcoid may present with impressive cervical adenopathy, similar to ALPS or Rosai-Dorfman disease patients. Lymphadenopathy is present in 50 percent of patients with sarcoidosis, who often have weight loss, cough, fatigue, lethargy, bone and joint pain, anorexia, and headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/23\">",
"     23",
"    </a>",
"    ]. African-Americans represent two-thirds to three-fourths of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     MIMICS OF LYMPHADENOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that can mimic an enlarged lymph node include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30744/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection or stones in any of the salivary glands",
"     </li>",
"     <li>",
"      Congenital anomalies: branchial cleft cyst, cystic hygroma, thyroglossal duct cyst",
"     </li>",
"     <li>",
"      Thyroid nodule",
"     </li>",
"     <li>",
"      Soft-tissue swelling from trauma or an insect bite or sting",
"     </li>",
"     <li>",
"      Hematoma",
"     </li>",
"     <li>",
"      Inguinal hernia",
"     </li>",
"     <li>",
"      Hemangioma, lymphangioma",
"     </li>",
"     <li>",
"      Lipoma",
"     </li>",
"     <li>",
"      Dermoid",
"     </li>",
"     <li>",
"      Rheumatoid nodules",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/59/43955?source=see_link\">",
"       \"Patient information: Swollen neck nodes in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal lymph nodes in most regions usually are less than 1 cm in their longest diameter; normal lymph nodes in the epitrochlear region usually are less than 0.5 cm, and normal lymph nodes in the inguinal region usually are less than 1.5 cm. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy and definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lymphadenopathy can be caused by a vast array of diseases and drugs (",
"      <a class=\"graphic graphic_table graphicRef77382 \" href=\"mobipreview.htm?24/2/24620\">",
"       table 1",
"      </a>",
"      ). It is clinically useful to classify the causes of lymphadenopathy according to whether the lymphadenopathy is localized or generalized. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Localized lymphadenopathy is present in only one region. Causes of localized lymphadenopathy are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef61046 \" href=\"mobipreview.htm?7/17/7451\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Localized lymphadenopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Generalized lymphadenopathy is present in two or more noncontiguous regions. Causes of generalized lymphadenopathy are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef71073 \" href=\"mobipreview.htm?14/41/15005\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Generalized lymphadenopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Uncommon but important causes of peripheral lymphadenopathy in children include malignancy, Kawasaki disease, tularemia, Langerhans cell histiocytosis, hemophagocytic lymphohistiocytosis, autoimmune lymphoproliferative disease, Rosai-Dorfman disease, Kikuchi disease, inflammatory pseudotumor, and Churg-Strauss syndrome. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Uncommon but important causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unexplained localized (nonsupraclavicular) lymphadenopathy in children without other symptoms usually can be safely managed by two to three weeks of observation, as long as the children return for follow-up. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=see_link&amp;anchor=H20#H20\">",
"       \"Approach to the child with peripheral lymphadenopathy\", section on 'Localized nodes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Malignancy should be considered in children with peripheral lymphadenopathy and weight loss, abnormal complete blood count (CBC) or chest radiograph, generalized adenopathy without a clear etiology, fever &gt;1 week, and lack of upper respiratory tract infection symptoms. Immediate biopsy is indicated in such children. In conjunction with the other reasons for biopsy (weight loss, abnormal CBC, etc), lymph node biopsy also may be indicated in children with persistently elevated erythrocyte sedimentation rate (ESR) or rising ESR despite antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Malignancy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=see_link&amp;anchor=H14#H14\">",
"       \"Approach to the child with peripheral lymphadenopathy\", section on 'Lymph node biopsy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jackson, MA, Chesney, PJ. Lymphatic system and generalized lymphadenopathy. In: Principles and Practice of Pediatric Infectious Disease, 2nd, Long, SS, Pickering, LK, Prober, CG (Eds), Churchill Livingstone, New York 2008. p.135.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/2\">",
"      Herzog LW. Prevalence of lymphadenopathy of the head and neck in infants and children. Clin Pediatr (Phila) 1983; 22:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/3\">",
"      Knight PJ, Mulne AF, Vassy LE. When is lymph node biopsy indicated in children with enlarged peripheral nodes? Pediatrics 1982; 69:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/4\">",
"      Ferrer R. Lymphadenopathy: differential diagnosis and evaluation. Am Fam Physician 1998; 58:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/5\">",
"      HEINRICH WA, JUDD ES Jr. A critical analysis of biopsy of lymph nodes. Proc Staff Meet Mayo Clin 1948; 23:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/6\">",
"      Lake AM, Oski FA. Peripheral lymphadenopathy in childhood. Ten-year experience with excisional biopsy. Am J Dis Child 1978; 132:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/7\">",
"      Soldes OS, Younger JG, Hirschl RB. Predictors of malignancy in childhood peripheral lymphadenopathy. J Pediatr Surg 1999; 34:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/8\">",
"      Barton LL, Feigin RD. Childhood cervical lymphadenitis: a reappraisal. J Pediatr 1974; 84:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/9\">",
"      Williamson HA Jr. Lymphadenopathy in a family practice: a descriptive study of 249 cases. J Fam Pract 1985; 20:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/10\">",
"      Lai KK, Stottmeier KD, Sherman IH, McCabe WR. Mycobacterial cervical lymphadenopathy. Relation of etiologic agents to age. JAMA 1984; 251:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/11\">",
"      Spark RP, Fried ML, Bean CK, et al. Nontuberculous mycobacterial adenitis of childhood. The ten-year experience at a community hospital. Am J Dis Child 1988; 142:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/12\">",
"      Gaines H, von Sydow M, Pehrson PO, Lundbegh P. Clinical picture of primary HIV infection presenting as a glandular-fever-like illness. BMJ 1988; 297:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/13\">",
"      Sneller MC, Wang J, Dale JK, et al. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997; 89:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/14\">",
"      McAlister WH, Herman T, Dehner LP. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Pediatr Radiol 1990; 20:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/15\">",
"      Horneff G, J&uuml;rgens H, Hort W, et al. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): response to methotrexate and mercaptopurine. Med Pediatr Oncol 1996; 27:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/16\">",
"      Pulsoni A, Anghel G, Falcucci P, et al. Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review. Am J Hematol 2002; 69:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/17\">",
"      Lee KY, Yeon YH, Lee BC. Kikuchi-Fujimoto disease with prolonged fever in children. Pediatrics 2004; 114:e752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/18\">",
"      La Barge DV 3rd, Salzman KL, Harnsberger HR, et al. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): imaging manifestations in the head and neck. AJR Am J Roentgenol 2008; 191:W299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/19\">",
"      Raslan OA, Schellingerhout D, Fuller GN, Ketonen LM. Rosai-Dorfman disease in neuroradiology: imaging findings in a series of 10 patients. AJR Am J Roentgenol 2011; 196:W187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/20\">",
"      Payne JH, Evans M, Gerrard MP. Kikuchi-Fujimoto disease: a rare but important cause of lymphadenopathy. Acta Paediatr 2003; 92:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/21\">",
"      Moran CA, Suster S, Abbondanzo SL. Inflammatory pseudotumor of lymph nodes: a study of 25 cases with emphasis on morphological heterogeneity. Hum Pathol 1997; 28:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/22\">",
"      Casey M, Radel E, Ratech H. Lymph node manifestations of limited Churg-Strauss syndrome. J Pediatr Hematol Oncol 2000; 22:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/23\">",
"      Pattishall EN, Strope GL, Spinola SM, Denny FW. Childhood sarcoidosis. J Pediatr 1986; 108:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/24\">",
"      Torsiglieri AJ Jr, Tom LW, Ross AJ 3rd, et al. Pediatric neck masses: guidelines for evaluation. Int J Pediatr Otorhinolaryngol 1988; 16:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/25\">",
"      Margileth AM. Sorting out the causes of lymphadenopathy. Contemp Pediatr 1995; 12:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30744/abstract/26\">",
"      Yaris N, Cakir M, S&ouml;zen E, Cobanoglu U. Analysis of children with peripheral lymphadenopathy. Clin Pediatr (Phila) 2006; 45:544.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2871 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30744=[""].join("\n");
var outline_f30_1_30744=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LOCALIZED LYMPHADENOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cervical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Supraclavicular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Axillary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inguinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Epitrochlear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GENERALIZED LYMPHADENOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Mononucleosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - HIV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      UNCOMMON BUT IMPORTANT CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Tularemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Chronic granulomatous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Autoimmune lymphoproliferative disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Rosai-Dorfman disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Kikuchi disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Inflammatory pseudotumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Churg-Strauss syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      MIMICS OF LYMPHADENOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2871\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2871|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/53/19285\" title=\"figure 1\">",
"      Lymph nodes head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/27/2482\" title=\"figure 2\">",
"      Lymph node groups body",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2871|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/6/18542\" title=\"picture 1\">",
"      Staphylococcal adenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/60/41934\" title=\"picture 2\">",
"      Mycobacterium avium adenitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/51/26418\" title=\"picture 3\">",
"      Tularemia eschar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/19/5439\" title=\"picture 4\">",
"      Tularemia adenitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2871|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/2/24620\" title=\"table 1\">",
"      Causes of lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/17/7451\" title=\"table 2\">",
"      Drugs causing lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/41/15005\" title=\"table 3\">",
"      Causes localized lymphadenopathy in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/44/9933\" title=\"table 4A\">",
"      Infectious causes generalized lymphadenopathy children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/35/31293\" title=\"table 4B\">",
"      Noninfectious causes generalized lymphadenopathy in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33128?source=related_link\">",
"      Approach to the child with peripheral lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30279?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/58/30629?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/246?source=related_link\">",
"      Autoimmune lymphoproliferative syndrome (ALPS): Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/51/6970?source=related_link\">",
"      Castleman's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/17/24857?source=related_link\">",
"      Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/22/34150?source=related_link\">",
"      Epidemiology and pathology of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14166?source=related_link\">",
"      Epidemiology, microbiology, and pathogenesis of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/27/8632?source=related_link\">",
"      Etiology and clinical manifestations of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/10/39080?source=related_link\">",
"      Evaluation of peripheral lymphadenopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27303?source=related_link\">",
"      Hematologic problems in children and adolescents with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28647?source=related_link\">",
"      Kikuchi's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23289?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32874?source=related_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/42/13994?source=related_link\">",
"      Overview of nontuberculous mycobacterial lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/59/43955?source=related_link\">",
"      Patient information: Swollen neck nodes in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_1_30745="Stress-induced (takotsubo) cardiomyopathy";
var content_f30_1_30745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stress-induced (takotsubo) cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/1/30745/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30745/contributors\">",
"     Guy S Reeder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30745/contributors\">",
"     Abhiram Prasad, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/1/30745/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30745/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/1/30745/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30745/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/1/30745/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress-induced cardiomyopathy, also called apical ballooning syndrome, broken heart syndrome, and takotsubo cardiomyopathy, is an increasingly reported syndrome generally characterized by transient systolic dysfunction of the apical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mid segments of the left ventricle that mimics myocardial infarction (MI), but in the absence of obstructive coronary artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/1-15\">",
"     1-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stress-induced cardiomyopathy was first described in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] and was subsequently reported in non-Asian populations, including the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/6,7,10\">",
"     6,7,10",
"    </a>",
"    ] and Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/9,16\">",
"     9,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term &ldquo;takotsubo&rdquo; is taken from the Japanese name for an octopus trap, which has a shape that is similar to the apical ballooning configuration of the left ventricle (LV) in systole in the \"typical\" form of this disorder. In the more commonly described \"typical\" type of stress-induced cardiomyopathy, the contractile function of the mid and apical segments of the LV are depressed, and there is compensatory hyperkinesis of the basal walls, producing a balloon-like appearance of the distal ventricle with systole. Less commonly (17 percent of cases in one series), the ventricular hypokinesis is restricted to the midventricle (\"atypical\") with relative sparing of the apex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/17\">",
"     17",
"    </a>",
"    ]. About a third of cases involve both right and left ventricles.",
"   </p>",
"   <p>",
"    Stress-induced cardiomyopathy is much more common in women than men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3,4,7,15,16\">",
"     3,4,7,15,16",
"    </a>",
"    ]. In a review of ten prospective series, women accounted for 80 to 100 percent of cases, with a mean age of 61 to 76 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of stress-induced cardiomyopathy is frequently but not always triggered by an acute medical illness or by intense emotional or physical stress (eg, death of relatives, particularly if unexpected, domestic abuse, arguments, catastrophic medical diagnoses, devastating financial or gambling losses, natural disasters) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/4,5,7-10,18\">",
"     4,5,7-10,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of this disorder is not well understood. It is not known why this disorder affects postmenopausal women disproportionately or why the left ventricular mid-cavity and apex are predominantly affected. Although the clinical presentation simulates that of an acute MI, coronary arteriography typically shows no obstructive lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/4,7\">",
"     4,7",
"    </a>",
"    ], and only a minority of patients display coronary spasm with acetylcholine provocation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postulated mechanisms include catecholamine excess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/8,19\">",
"     8,19",
"    </a>",
"    ], coronary artery spasm, and microvascular dysfunction. Alternatively, there may be dynamic mid-cavity or left ventricular outflow tract obstruction which may contribute to apical dysfunction. Analogous permanent (rather than transient) apical outpouchings develop in patients with hypertrophic cardiomyopathy and mid-ventricular obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=see_link&amp;anchor=H4#H4\">",
"     \"Types and pathophysiology of obstructive hypertrophic cardiomyopathy\", section on 'Midcavity obstructive HCM'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potential role for plaque rupture and thrombosis with spontaneous thrombolysis has not been established and the results of intravascular ultrasound (IVUS) studies are mixed. Although one IVUS study found evidence of mid left anterior descending (LAD) coronary artery plaque rupture in 5 of 5 patients diagnosed with stress-induced cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/20\">",
"     20",
"    </a>",
"    ], other IVUS series found no evidence of culprit lesions in the LAD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Physical or emotional stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of features of stress-induced cardiomyopathy, including its association with physical or emotional stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/4,5,7-10,18\">",
"     4,5,7-10,18",
"    </a>",
"    ], suggest that this disorder may be caused by diffuse catecholamine-induced microvascular spasm or dysfunction, resulting in myocardial stunning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/23\">",
"     23",
"    </a>",
"    ], or by direct catecholamine-associated myocardial toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/24\">",
"     24",
"    </a>",
"    ]. In some patients with stress-induced cardiomyopathy, the only apparent stressor is exposure to catecholamine or beta-agonist drugs in routine clinical doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/35/8759?source=see_link\">",
"     \"Clinical syndromes of stunned or hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Support for a possible pathogenic role for catecholamines comes from studies in which plasma catecholamines were measured at presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/8,26-28\">",
"     8,26-28",
"    </a>",
"    ]. Combining the results from these series, plasma norepinephrine levels were elevated in 26 of 35 patients (74 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/23\">",
"     23",
"    </a>",
"    ]. Elevated catecholamine levels and reversible left ventricular ballooning have also been observed in a rat model of immobilization-induced stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of catecholamine excess associated with this disorder was illustrated in a report that measured plasma catecholamine levels in 13 patients with stress-induced cardiomyopathy and seven patients with a Killip class III MI (",
"    <a class=\"graphic graphic_table graphicRef65592 \" href=\"mobipreview.htm?3/59/4027\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/8\">",
"     8",
"    </a>",
"    ]. Plasma catecholamines were significantly higher in the patients with stress-induced cardiomyopathy as compared to those with MI: epinephrine (1264 versus 376",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    and norepinephrine (2284 versus 1100",
"    <span class=\"nowrap\">",
"     pg/mL).",
"    </span>",
"    However, elevation in blood catecholamine levels is not uniformly present and some studies have reported normal levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further support for the catecholamine hypothesis is provided by observations of a similar reversible cardiomyopathy with global or focal dysfunction in patients with pheochromocytoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/31\">",
"     31",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    ), and in the setting of acute brain injury, which has also been postulated to be related to catecholamine excess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26952?source=see_link&amp;anchor=H140695105#H140695105\">",
"     \"Cardiac complications of stroke\", section on 'Neurogenic cardiac damage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations support the hypothesis of vascular dysfunction that may be catecholamine-induced:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The occasional finding of multifocal coronary vasospasm on coronary angiography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/4,7,33\">",
"       4,7,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transient myocardial perfusion abnormalities that resolve with improvement in the myopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of abnormal TIMI frame counts on angiography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/10\">",
"       10",
"      </a>",
"      ]. The TIMI frame count is the number of cine frames required for dye to first reach standardized distal coronary landmarks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=see_link&amp;anchor=H5#H5\">",
"       \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI frame count'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following observations support the hypothesis of catecholamine-induced myocardial effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited available endomyocardial biopsy data [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/5,8,24\">",
"       5,8,24",
"      </a>",
"      ] are consistent with histologic signs of catecholamine toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. Findings have ranged from no evidence of myocarditis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/33\">",
"       33",
"      </a>",
"      ] to interstitial fibrosis with or without slight cellular infiltration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/5\">",
"       5",
"      </a>",
"      ] to mononuclear infiltrates with contraction band necrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/8\">",
"       8",
"      </a>",
"      ]. In a series of eight patients, acute biopsies obtained during the period of left ventricular dysfunction revealed intracellular accumulation of glycogen, many vacuoles, disorganized cytoskeletal and contractile structure, contraction bands and increased extracellular matrix proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/24\">",
"       24",
"      </a>",
"      ]. These alterations resolved nearly completely after functional recovery.",
"     </li>",
"     <li>",
"      In a mouse model, it has been demonstrated that a high level of epinephrine is negatively inotropic due to a switch from beta-2 adrenoreceptor mediated Gs protein signaling, which is positively inotropic, to Gi protein signaling which is negatively inotropic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/36\">",
"       36",
"      </a>",
"      ]. It is speculated that the greater effect at the apical myocardium may be due to a higher density of beta-adrenoreceptors at this location [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since stress-induced cardiomyopathy occurs in a minority of postmenopausal women, it is likely that predisposing factors increase susceptibility in some individuals. Recently, there have been two reports of familial cases involving two sisters in one family and a mother and daughter in another family raising the possibility of a genetic predisposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. However, early genetic analyses have not identified a mutation or polymorphism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Moreover, there may be a higher prevalence of chronic anxiety disorders preceding the illness in patients with stress induced cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Critical illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of stress-induced cardiomyopathy in a medical intensive care unit (ICU) population was prospectively evaluated in a series of 92 patients with a non-cardiac diagnosis and no prior history of cardiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/43\">",
"     43",
"    </a>",
"    ]. All patients underwent serial echocardiography on admission and on hospital days three and seven, specifically evaluated for LV apical ballooning. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      26 patients had LV apical ballooning (21 on admission), with an average left ventricular ejection fraction (LVEF) of 33 percent.",
"     </li>",
"     <li>",
"      Left ventricular function normalized in 20 patients at a mean of seven days.",
"     </li>",
"     <li>",
"      In multivariable analysis, sepsis was the only predictor of LV apical ballooning.",
"     </li>",
"     <li>",
"      LV apical ballooning predicted lower two-month survival (52 versus 71 percent without this finding).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The high incidence of transient LV apical ballooning in this series requires validation in larger series, but it appears that this phenomenon is not uncommon in a medical ICU population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the best available estimates come from four small series of consecutive patients presenting with a suspected acute coronary syndrome (ACS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/10,26,27,44\">",
"     10,26,27,44",
"    </a>",
"    ], which were included in a larger systematic review [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/23\">",
"     23",
"    </a>",
"    ]. Each of these series included 10 to 16 patients with stress-induced cardiomyopathy, accounting for approximately 1.7 to 2.2 percent of cases presenting with suspected ACS. A similar prevalence of 1.2 percent was reported from a registry of 3265 patients with troponin-positive ACS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of stress-induced cardiomyopathy is similar to that of an acute MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3,4,7\">",
"     3,4,7",
"    </a>",
"    ]. The most common presenting symptom is acute substernal chest pain, but some patients present with dyspnea, syncope, shock, or electrocardiographic abnormalities.",
"   </p>",
"   <p>",
"    Acute complications of stress-induced cardiomyopathy can include heart failure, tachyarrhythmias (including ventricular tachycardia and ventricular fibrillation), bradyarrhythmias, mitral regurgitation and cardiogenic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3,4,7,9\">",
"     3,4,7,9",
"    </a>",
"    ]. In a review of 12 prospective series (with 13 to 88 subjects), pulmonary edema occurred in 0 to 44 percent of cases and intra-aortic balloon counterpulsation was used in 0 to 18 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/15\">",
"     15",
"    </a>",
"    ]. Left ventricular outflow tract (LVOT) obstruction, induced by left ventricular basal hyperkinesis, can contribute to the development of shock and cause severe mitral regurgitation or the murmur of hypertrophic cardiomyopathy (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link&amp;anchor=H18#H18\">",
"     \"Auscultation of cardiac murmurs\", section on 'Subvalvular outflow obstruction'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/45\">",
"     45",
"    </a>",
"    ]. Apical thrombus formation and stroke have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/25,46\">",
"     25,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A preliminary report proposed a risk score to predict the likelihood of acute heart failure based on the presence or absence of the following three variables: age &gt;70 years, presence of a physical stressor, and left ventricular ejection fraction (LVEF) &lt;40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/47\">",
"     47",
"    </a>",
"    ]. In the development cohort of 118 patients, the likelihood of developing acute heart failure was &lt;10 percent in the absence of these risk factors. With one, two, or three risk factors present, the risk was approximately 28, 58, and 85 percent, respectively. A similar gradient of risk was observed when the risk score was applied to the 52 patients in the validation cohort.",
"   </p>",
"   <p>",
"    Data on the characteristics of stress-induced cardiomyopathy come from relatively small case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3-5,7-10,26,45,48,49\">",
"     3-5,7-10,26,45,48,49",
"    </a>",
"    ]. A systematic review of 14 series, including a total of 286 patients, provides a more comprehensive assessment of this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/23\">",
"     23",
"    </a>",
"    ]. The range of findings from these reports is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrocardiographic abnormalities are the most common finding. ST segment elevation was present in 34 to 56 percent of patients in the systematic review [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. Among these patients, ST segment elevation was most common in the anterior precordial leads. The remaining patients had deep T wave inversion with QT interval prolongation, abnormal Q waves, non-specific abnormalities, and in some cases the ECG is normal at presentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/4,8,48\">",
"       4,8,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac biomarker levels, particularly high-sensitivity troponin assays, are usually elevated. However, the elevations are typically mild, which contrasts with the often severe hemodynamic compromise. In the systematic review, among studies that measured cardiac troponins or creatine kinase MB, these levels were elevated in 86 and 74 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/23\">",
"       23",
"      </a>",
"      ]. In a later series of 136 patients, troponin T levels ranged from 0.01 to 5.2",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Left ventriculography or echocardiography usually show the characteristic apical ballooning with akinesis or dyskinesis of the apical one-half to two-thirds of the LV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3-5,7-9,23,26\">",
"       3-5,7-9,23,26",
"      </a>",
"      ]. Overall systolic function is reduced, and the reported average LVEF has ranged from 20 to 49 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/4,7,8,23\">",
"       4,7,8,23",
"      </a>",
"      ]. Apical sparing variant accounts for a significant proportion of patients, though the clinical characteristics of typical and apical sparing forms appear to be similar [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/11,32-36\">",
"       11,32-36",
"      </a>",
"      ]. No obvious mechanism for the different patterns of regional wall motion abnormality has been identified.",
"     </li>",
"     <li>",
"      In the systematic review, transient LVOT obstruction was reported in 16 percent of the patients (21 of 133) who underwent left ventriculography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/23\">",
"       23",
"      </a>",
"      ]. In some cases, this is accompanied by systolic anterior motion of the mitral valve, similar to that seen in hypertrophic cardiomyopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reversible perfusion abnormalities in the left ventricular apex have been documented [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3,5\">",
"       3,5",
"      </a>",
"      ], while cardiovascular magnetic resonance imaging (CMRI) typically shows mid and apical LV segmental wall motion abnormalities, often in multiple coronary territories without delayed hyperenhancement of involved regions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/7,51\">",
"       7,51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of stress-induced cardiomyopathy should be suspected in postmenopausal women who present with an acute coronary syndrome after intense psychologic stress in whom the clinical manifestations and ECG abnormalities are out of proportion to the degree of elevation in cardiac biomarkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/11\">",
"     11",
"    </a>",
"    ]. Apical ballooning (typical variant)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    midventricular hypokinesis is usually seen on left ventriculography or echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3-5,7,9,16,26\">",
"     3-5,7,9,16,26",
"    </a>",
"    ]. In a minority of cases, the transient left ventricular hypokinesis is restricted to the midventricular segments (\"atypical variant\" or &ldquo;apical sparing variant&rdquo;) without involvement of the apex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/16\">",
"     16",
"    </a>",
"    ]. In one series of 256 patients, 82 percent were apical, 17 percent midventricular, and 1 percent basal, with 34 percent of cases demonstrating right ventricular involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coronary angiography typically demonstrates either normal vessels or mild to moderate coronary atherosclerosis. Obstructive coronary artery disease may rarely coexist by virtue of its prevalence in the population at risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/52\">",
"     52",
"    </a>",
"    ]. Some investigators have hypothesized that stress cardiomyopathy is not a distinct clinical entity, but rather a manifestation of aborted anterior MI in patients with a long &lsquo;wrap around&rsquo; left anterior descending artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/20\">",
"     20",
"    </a>",
"    ]. Transient occlusion in such a vessel, with subsequent spontaneous thrombus lysis, could produce apical stunning and wall-motion abnormalities that would improve over followup. However, in one series the prevalence of &lsquo;wrap-around&rsquo; left anterior descending artery in stress-induced cardiomyopathy was found to be low (27 percent) and comparable to that in patients diagnosed with anterior ST elevation MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following cardiac magnetic resonance (CMR) imaging features may be helpful in the diagnosis of stress-induced cardiomyopathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late gadolinium enhancement (LGE) on CMR is generally absent in stress-induced cardiomyopathy in contrast to myocardial infarction in which intense (ie, &gt;5 standard deviations above the mean signal intensity of remote myocardium) subendocardial or transmural LGE is seen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/5,11,17,40,41\">",
"       5,11,17,40,41",
"      </a>",
"      ]. LGE is also useful in differentiating stress-induced cardiomyopathy from myocarditis, which is characterized by patchy late gadolinium enhancement. However, when a low threshold for LGE is used (eg, three standard deviations above the mean signal intensity of remote myocardium), LGE is occasionally detected in stress-induced cardiomyopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=see_link&amp;anchor=H36992798#H36992798\">",
"       \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Late gadolinium enhancement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CMR evidence of myocardial edema is commonly seen in stress-induced cardiomyopathy. However, myocardial edema is also seen in acute myocardial infarction and myocarditis. In one series, 81 percent of patients had evidence of focal myocardial edema on CMR and these regions corresponded to areas of wall motion abnormality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CMR may also enable identification of thrombus in the left or right ventricle, which may not be detected by echocardiography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of other syndromes in addition to stress-induced cardiomyopathy have been associated with ST segment changes in the absence of significant coronary artery disease, including cardiac syndrome X, variant (Prinzmetal's) angina, myocarditis, and cocaine abuse. As noted above, similar reversible cardiomyopathy with global or focal dysfunction has been observed in patients with pheochromocytoma and in the setting of acute brain injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. These conditions are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=see_link&amp;anchor=H4#H4\">",
"     \"Cardiac syndrome X: Angina pectoris with normal coronary arteries\", section on 'Acute coronary syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3706?source=see_link\">",
"     \"Variant angina\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26952?source=see_link&amp;anchor=H140695105#H140695105\">",
"     \"Cardiac complications of stroke\", section on 'Neurogenic cardiac damage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are the proposed Mayo Clinic diagnostic criteria, all four of which are required for the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transient hypokinesis, akinesis or dyskinesis of the left ventricular mid segments with or without apical involvement. The regional wall motion abnormalities typically extend beyond a single epicardial coronary distribution. A stressful trigger is often, but not always present.",
"     </li>",
"     <li>",
"      Absence of obstructive coronary disease or angiographic evidence of acute plaque rupture.",
"     </li>",
"     <li>",
"      New electrocardiographic abnormalities (either ST-segment elevation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      T wave inversion) or modest elevation in cardiac troponin.",
"     </li>",
"     <li>",
"      Absence of pheochromocytoma or myocarditis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are rare exceptions to these criteria such as patients in whom the regional wall motion abnormality is limited to a single coronary territory, and the occasional patient with obstructive coronary atherosclerosis who develops stress-induced cardiomyopathy.",
"   </p>",
"   <p>",
"    An important issue is how the possible diagnosis of stress-induced cardiomyopathy should influence the evaluation of a suspected acute coronary syndrome. We suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients presenting with ST elevation who can undergo urgent cardiac catheterization for the purpose of primary PCI should proceed with angiography in the usual manner. If the patient has stress-induced cardiomyopathy, angiographic findings will suggest the diagnosis by showing no critical coronary disease and the presence of apical ballooning (or mid wall hypokinesis) on left ventricular angiography. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link\">",
"       \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with ST elevation meeting criteria for reperfusion therapy presenting in a setting without availability of urgent angiography and PCI are usually treated with fibrinolytic therapy. In such cases, suspicion of the diagnosis of stress-induced cardiomyopathy is not a sufficient reason to withhold fibrinolytic therapy since the majority of patients with acute ST elevation will have a critical coronary lesion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link\">",
"       \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the later scenario, the diagnosis of stress-induced cardiomyopathy may later be suggested by such clinical features as the absence of critical stenoses on coronary angiography, modest cardiac enzyme elevations and recovery of LV function. However, none of these features is diagnostic, as they may also reflect successful early fibrinolysis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who present without ST elevation will usually fit into a \"high risk\" NSTEMI profile (positive troponin, elderly, significant left ventricular dysfunction). Early (less than 48 hours) cardiac catheterization will be performed in most such patients, which should suggest the correct diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link\">",
"       \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients for whom both cardiac catheterization and thrombolytic therapy are relatively contraindicated are problematic. In these patients, the pattern of wall motion abnormality may differ between individuals with stress-induced cardiomyopathy and those with acute obstruction of flow in the left anterior descending coronary artery. The former had significantly more dysfunction of the right ventricular free and left ventricular lateral walls than the latter in a small, retrospective echocardiographic study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/53\">",
"       53",
"      </a>",
"      ]. The wall motion abnormalities in stress-induced cardiomyopathy typically involve the distribution of more than one coronary artery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Right ventricular involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most reports of stress-induced cardiomyopathy have focused on transient dysfunction of the left ventricle. However, there is emerging evidence that the right ventricle (RV) is also affected in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency and significance of RV involvement was illustrated in a series of 34 patients with stress-induced cardiomyopathy who underwent cardiac magnetic resonance (CMR) imaging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/55\">",
"     55",
"    </a>",
"    ]. Nine patients (26 percent) had RV wall motion abnormalities. Patients with RV dysfunction had lower LV ejection fractions compared to patients with normal RV function (40 versus 48 percent), and were also more likely to have pleural effusions. At a mean of one year after presentation, follow-up CMR showed improvement or resolution of RV dysfunction in eight of nine patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the severity of the acute illness, stress-induced cardiomyopathy is a transient disorder managed with supportive therapy. Conservative treatment with resolution of the physical or emotional stress usually results in rapid resolution of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     General therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of stress-induced cardiomyopathy has been made, therapy is based upon the patient's overall clinical condition. There are no controlled data to define the optimal medical regimen, but it is reasonable to treat these patients with standard medications for left ventricular systolic dysfunction. These include ACE inhibitors, beta blockers, and diuretics as necessary for volume overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3\">",
"     3",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is also suggested in the presence of coexisting coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stress-induced cardiomyopathy is a transient disorder. In the absence of clinical trial data, the appropriate duration of therapy is not known. We usually treat patients with the standard HF medical regimen until there is recovery of systolic function which occurs in one to four weeks in most cases. However, because the condition may recur, we often continue adrenergic blockade with either beta-blockers or combined alpha and beta-blockers indefinitely in the absence of contraindications or intolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hypotension and shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are in shock should undergo urgent echocardiography to determine if left ventricular outflow tract (LVOT) obstruction is present, which has been described in 13 to 18 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3,45\">",
"     3,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Without left ventricular outflow tract obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without significant LVOT obstruction who are hypotensive due to pump dysfunction can be treated cautiously with inotropes such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    . Since the condition is potentially caused by catecholamine excess, the impact of sympathomimetics remains to be established. In a patient with hypotension due to pump failure, inotropic agents may induce LVOT obstruction, but the degree is usually mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/7\">",
"     7",
"    </a>",
"    ]. A change in the therapeutic approach is not necessary if mild LVOT obstruction develops. Intra-aortic balloon counterpulsation (IABP) is the preferred therapy when there is marked LV dysfunction associated with severe hypotension or shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     With left ventricular outflow tract obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to hypotension due only to pump failure, hypotension associated with LVOT obstruction should NOT be treated with inotropic agents, because they can worsen the degree of obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/7,45\">",
"     7,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended approach to patients with moderate-to-severe LVOT obstruction includes the use of beta blockers, which can improve hemodynamics by causing resolution of the obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10105?source=see_link\">",
"     \"Medical therapy in hypertrophic cardiomyopathy\"",
"    </a>",
"    .) In addition, in the absence of significant pulmonary congestion, the patient should be fluid resuscitated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3,45\">",
"     3,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with patients in shock due to pump failure, those with LVOT obstruction may benefit from an IABP, although there is a slight risk that afterload reduction from the IABP will worsen the degree of obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/7\">",
"     7",
"    </a>",
"    ]. The initial treatment in such patients, however, should be to treat the underlying pathophysiological mechanisms with fluid replacement, beta blockers, and other negative inotropic agents. In patients with hypotension, whether with or without significant LVOT obstruction, who do not respond to initial medical therapy and volume resuscitation, we suggest the use of an IABP.",
"   </p>",
"   <p>",
"    In patients with LVOT obstruction and severe hypotension who either do not tolerate or do not adequately respond to beta blockers, an alpha agonist may be added with caution and close monitoring.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     Phenylephrine",
"    </a>",
"    is a pure alpha-adrenergic agonist that may reduce the gradient by increasing afterload, thereby improving overall hemodynamics. This treatment may be helpful to support blood pressure while a beta blocker is administered to reduce inotropy. However, the vasoconstrictive effects of alpha agonists may be harmful, particularly in these patients who can be prone to coronary vasospasm. Thus, if phenylephrine is used, it should be done with a high degree of caution and very close monitoring of hemodynamics and tissue perfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9872698\">",
"    <span class=\"h2\">",
"     Thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential risk of intraventricular thrombus formation and systemic embolization should be addressed. Echocardiography (and CMR if available) should include evaluation for potential thrombus as well as assessment of the extent of wall motion abnormality.",
"   </p>",
"   <p>",
"    Data are scant to identify suitable criteria for use of anticoagulation to prevent thromboembolism in patients with stress cardiomyopathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indirect data are available from randomized trials of anticoagulation to prevent left ventricular thrombus in patients with acute myocardial infarction. As discussed in detail separately, these trials found that about 10 days of anticoagulation reduced the incidence of LV thrombus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5497?source=see_link&amp;anchor=H10#H10\">",
"       \"Left ventricular thrombus after acute myocardial infarction\", section on 'Prevention of formation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of anticoagulation to prevent embolization in patients with known LV thrombus is supported by indirect data from observational studies in patients with LV thrombus after MI. In these studies, anticoagulation during a period of four to six months was associated with a reduced rate of embolization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5497?source=see_link&amp;anchor=H16390532#H16390532\">",
"       \"Left ventricular thrombus after acute myocardial infarction\", section on 'Prevention of embolization'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend approximately three months of anticoagulation if intraventricular thrombus is detected. The duration of anticoagulation may be modified based on the rate of recovery of cardiac function and resolution of the thrombus. For patients without thrombus but with severe left ventricular dysfunction, we suggest anticoagulation until akinesis or dyskinesis has resolved or for three months, whichever is shorter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported in-hospital mortality rates have ranged from 0 to 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3,4,7,15\">",
"     3,4,7,15",
"    </a>",
"    ]. In a large series of 136 patients, there were three in-hospital deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients who survive the acute episode typically recover normal ventricular function within one to four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/4,7-9,33\">",
"     4,7-9,33",
"    </a>",
"    ]. In two series, for example, the mean LVEF increased from 29 percent at presentation to 63 percent at a mean of six days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/7\">",
"     7",
"    </a>",
"    ] and from a median of 20 percent at presentation to 60 percent at two to four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The longest follow-up data comes from a study of 100 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30745/abstract/56\">",
"     56",
"    </a>",
"    ]. Over a mean follow-up of 4.4 &plusmn; 4.6 years, 31 patients continued to have episodes of chest pain and 10 patients had recurrence of apical ballooning syndrome. Seventeen patients died, but there was no difference in survival compared to an age- and gender-matched population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/6/35938?source=see_link\">",
"       \"Patient information: Stress-induced cardiomyopathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress-induced cardiomyopathy is an increasingly reported syndrome characterized by transient regional LV dysfunction in the absence of significant coronary artery disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clinical manifestations and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stress-induced cardiomyopathy is typically triggered by an acute medical illness or by intense emotional or physical stress, although a triggering event is not always present. Postulated pathogenic mechanisms include catecholamine excess, multivessel coronary artery spasm, and microvascular dysfunction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stress-induced cardiomyopathy may account for approximately 2 percent of suspected acute coronary syndromes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common presenting features include ECG abnormalities (often anterior ST elevations), elevated cardiac biomarkers, substernal chest pain, and dyspnea. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proposed diagnostic criteria include presence of transient regional wall motion abnormalities (typically not in a single coronary distribution), absence of angiographic evidence of obstructive coronary disease or acute plaque rupture, presence of new ECG abnormalities or modest troponin elevation, AND absence of pheochromocytoma or myocarditis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute complications of stress-induced cardiomyopathy include acute heart failure, cardiogenic shock, transient LVOT obstruction, tachyarrhythmias, and bradyarrhythmias (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In-hospital mortality is approximately 2 percent. Patients who survive the acute episode typically recover normal LV function within one to four weeks. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of stress-induced cardiomyopathy is largely supportive, including hydration and an attempt to alleviate the triggering physical or emotional stress. The role of additional medications and the appropriate duration of therapy are not established. Most experts favor at least the short-term use of standard medications for heart failure due to systolic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who present with a clinical picture consistent with an ST elevation MI, the suspicion of stress-induced cardiomyopathy is not a reason to alter management. The significant majority of these cases are due to occlusion of a coronary artery and revascularization therapy should not be delayed. We recommend that such patients be managed in the conventional manner, either with urgent catheterization and PCI or with fibrinolytic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=see_link\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=see_link\">",
"       \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We approach hemodynamically stable patients diagnosed with stress-induced cardiomyopathy in the following manner (see",
"    <a class=\"local\" href=\"#H11\">",
"     'General therapy'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest the initiation of a beta blocker (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients who do not have an LVOT gradient, we suggest the initiation of an ACE inhibitor or an angiotensin receptor blocker (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with heart failure who do not have an LVOT gradient, we suggest diuresis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in the presence of coexisting coronary atherosclerosis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend anticoagulation if intraventricular thrombus is detected (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We typically anticoagulate for three months. The duration of anticoagulation may be modified based on the rate of recovery of cardiac function and resolution of the thrombus.",
"     </li>",
"     <li>",
"      For patients without thrombus but with severe left ventricular dysfunction, we suggest anticoagulation until the akinesis or dyskinesis has resolved or for three months, whichever is shorter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with stress-induced cardiomyopathy will develop hypotension and shock, which could be due either to severe systolic dysfunction or to LVOT obstruction. Because it will influence the choice of treatment, patients who develop severe hypotension should undergo urgent echocardiography to determine if LVOT obstruction is present.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with hypotension, whether with or without significant LVOT obstruction, if significant pulmonary congestion is not present we suggest cautious fluid resuscitation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hypotension and shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with significant hypotension who do not have significant outflow obstruction, we suggest intravenous inotropes, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hypotension and shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with hypotension and moderate-to-severe LVOT obstruction, we suggest that inotropic agents not be used because they can worsen the degree of obstruction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hypotension and shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with hypotension and moderate-to-severe LVOT obstruction, we suggest beta blockers, which can improve hemodynamics by causing resolution of the obstruction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In patients with LVOT obstruction and severe hypotension who either do not tolerate or do not adequately respond to beta blockers, an alpha agonist may be added with caution and close monitoring. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hypotension and shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with hypotension, whether with or without significant LVOT obstruction, who do not respond to initial medical therapy and volume resuscitation, we suggest the use of an IABP (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hypotension and shock'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sato H, Taiteishi H, Uchida T. Takotsubo-type cardiomyopathy due to multivessel spasm. In: Clinical aspect of myocardial injury: From ischemia to heart failure, Kodama K, Haze K, Hon M (Eds), Kagakuhyouronsha, Tokyo 1990. p.56.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/2\">",
"      Dote K, Sato H, Tateishi H, et al. [Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases]. J Cardiol 1991; 21:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/3\">",
"      Bybee KA, Kara T, Prasad A, et al. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med 2004; 141:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/4\">",
"      Tsuchihashi K, Ueshima K, Uchida T, et al. Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. Angina Pectoris-Myocardial Infarction Investigations in Japan. J Am Coll Cardiol 2001; 38:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/5\">",
"      Abe Y, Kondo M, Matsuoka R, et al. Assessment of clinical features in transient left ventricular apical ballooning. J Am Coll Cardiol 2003; 41:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/6\">",
"      Hachamovitch R, Chang JD, Kuntz RE, et al. Recurrent reversible cardiogenic shock triggered by emotional distress with no obstructive coronary disease. Am Heart J 1995; 129:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/7\">",
"      Sharkey SW, Lesser JR, Zenovich AG, et al. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation 2005; 111:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/8\">",
"      Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005; 352:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/9\">",
"      Desmet WJ, Adriaenssens BF, Dens JA. Apical ballooning of the left ventricle: first series in white patients. Heart 2003; 89:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/10\">",
"      Bybee KA, Prasad A, Barsness GW, et al. Clinical characteristics and thrombolysis in myocardial infarction frame counts in women with transient left ventricular apical ballooning syndrome. Am J Cardiol 2004; 94:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/11\">",
"      Dec GW. Recognition of the apical ballooning syndrome in the United States. Circulation 2005; 111:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/12\">",
"      Aurigemma GP, Tighe DA. Echocardiography and reversible left ventricular dysfunction. Am J Med 2006; 119:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/13\">",
"      Bybee KA, Prasad A. Stress-related cardiomyopathy syndromes. Circulation 2008; 118:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/14\">",
"      Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J 2008; 155:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/15\">",
"      Akashi YJ, Goldstein DS, Barbaro G, Ueyama T. Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. Circulation 2008; 118:2754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/16\">",
"      Kurowski V, Kaiser A, von Hof K, et al. Apical and midventricular transient left ventricular dysfunction syndrome (tako-tsubo cardiomyopathy): frequency, mechanisms, and prognosis. Chest 2007; 132:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/17\">",
"      Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, et al. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA 2011; 306:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/18\">",
"      Watanabe H, Kodama M, Okura Y, et al. Impact of earthquakes on Takotsubo cardiomyopathy. JAMA 2005; 294:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/19\">",
"      Paur H, Wright PT, Sikkel MB, et al. High levels of circulating epinephrine trigger apical cardiodepression in a &beta;2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation 2012; 126:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/20\">",
"      Ibanez B, Navarro F, Cordoba M, et al. Tako-tsubo transient left ventricular apical ballooning: is intravascular ultrasound the key to resolve the enigma? Heart 2005; 91:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/21\">",
"      Haghi D, Roehm S, Hamm K, et al. Takotsubo cardiomyopathy is not due to plaque rupture: an intravascular ultrasound study. Clin Cardiol 2010; 33:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/22\">",
"      Delgado GA, Truesdell AG, Kirchner RM, et al. An angiographic and intravascular ultrasound study of the left anterior descending coronary artery in takotsubo cardiomyopathy. Am J Cardiol 2011; 108:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/23\">",
"      Gianni M, Dentali F, Grandi AM, et al. Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J 2006; 27:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/24\">",
"      Nef HM, M&ouml;llmann H, Kostin S, et al. Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery. Eur Heart J 2007; 28:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/25\">",
"      Sharkey SW, Windenburg DC, Lesser JR, et al. Natural history and expansive clinical profile of stress (tako-tsubo) cardiomyopathy. J Am Coll Cardiol 2010; 55:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/26\">",
"      Ito K, Sugihara H, Katoh S, et al. Assessment of Takotsubo (ampulla) cardiomyopathy using 99mTc-tetrofosmin myocardial SPECT--comparison with acute coronary syndrome. Ann Nucl Med 2003; 17:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/27\">",
"      Akashi YJ, Nakazawa K, Sakakibara M, et al. 123I-MIBG myocardial scintigraphy in patients with \"takotsubo\" cardiomyopathy. J Nucl Med 2004; 45:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/28\">",
"      Kurisu S, Inoue I, Kawagoe T, et al. Time course of electrocardiographic changes in patients with tako-tsubo syndrome: comparison with acute myocardial infarction with minimal enzymatic release. Circ J 2004; 68:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/29\">",
"      Ueyama T. Emotional stress-induced Tako-tsubo cardiomyopathy: animal model and molecular mechanism. Ann N Y Acad Sci 2004; 1018:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/30\">",
"      Madhavan M, Borlaug BA, Lerman A, et al. Stress hormone and circulating biomarker profile of apical ballooning syndrome (Takotsubo cardiomyopathy): insights into the clinical significance of B-type natriuretic peptide and troponin levels. Heart 2009; 95:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/31\">",
"      Kassim TA, Clarke DD, Mai VQ, et al. Catecholamine-induced cardiomyopathy. Endocr Pract 2008; 14:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/32\">",
"      Ako J, Sudhir K, Farouque HM, et al. Transient left ventricular dysfunction under severe stress: brain-heart relationship revisited. Am J Med 2006; 119:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/33\">",
"      Kurisu S, Sato H, Kawagoe T, et al. Tako-tsubo-like left ventricular dysfunction with ST-segment elevation: a novel cardiac syndrome mimicking acute myocardial infarction. Am Heart J 2002; 143:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/34\">",
"      Karch SB, Billingham ME. Myocardial contraction bands revisited. Hum Pathol 1986; 17:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/35\">",
"      Fineschi V, Silver MD, Karch SB, et al. Myocardial disarray: an architectural disorganization linked with adrenergic stress? Int J Cardiol 2005; 99:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/36\">",
"      Heubach JF, Ravens U, Kaumann AJ. Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human beta2-adrenoceptors overexpressed in mouse heart. Mol Pharmacol 2004; 65:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/37\">",
"      Lyon AR, Rees PS, Prasad S, et al. Stress (Takotsubo) cardiomyopathy--a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 2008; 5:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/38\">",
"      Pison L, De Vusser P, Mullens W. Apical ballooning in relatives. Heart 2004; 90:e67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/39\">",
"      Kumar G, Holmes DR Jr, Prasad A. \"Familial\" apical ballooning syndrome (Takotsubo cardiomyopathy). Int J Cardiol 2010; 144:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/40\">",
"      Handy AD, Prasad A, Olson TM. Investigating genetic variation of adrenergic receptors in familial stress cardiomyopathy (apical ballooning syndrome). J Cardiol 2009; 54:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/41\">",
"      Sharkey SW, Maron BJ, Nelson P, et al. Adrenergic receptor polymorphisms in patients with stress (tako-tsubo) cardiomyopathy. J Cardiol 2009; 53:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/42\">",
"      Summers MR, Lennon RJ, Prasad A. Pre-morbid psychiatric and cardiovascular diseases in apical ballooning syndrome (tako-tsubo/stress-induced cardiomyopathy): potential pre-disposing factors? J Am Coll Cardiol 2010; 55:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/43\">",
"      Park JH, Kang SJ, Song JK, et al. Left ventricular apical ballooning due to severe physical stress in patients admitted to the medical ICU. Chest 2005; 128:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/44\">",
"      Matsuoka K, Okubo S, Fujii E, et al. Evaluation of the arrhythmogenecity of stress-induced \"Takotsubo cardiomyopathy\" from the time course of the 12-lead surface electrocardiogram. Am J Cardiol 2003; 92:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/45\">",
"      Villareal RP, Achari A, Wilansky S, Wilson JM. Anteroapical stunning and left ventricular outflow tract obstruction. Mayo Clin Proc 2001; 76:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/46\">",
"      Barrera-Ramirez CF, Jimenez-Mazuecos JM, Alfonso F. Apical thrombus associated with left ventricular apical ballooning. Heart 2003; 89:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/47\">",
"      Madhavan M, Rihal CS, Lerman A, Prasad A. Acute heart failure in apical ballooning syndrome (TakoTsubo/stress cardiomyopathy): clinical correlates and Mayo Clinic risk score. J Am Coll Cardiol 2011; 57:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/48\">",
"      Ogura R, Hiasa Y, Takahashi T, et al. Specific findings of the standard 12-lead ECG in patients with 'Takotsubo' cardiomyopathy: comparison with the findings of acute anterior myocardial infarction. Circ J 2003; 67:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/49\">",
"      Sharkey SW, Lesser JR, Menon M, et al. Spectrum and significance of electrocardiographic patterns, troponin levels, and thrombolysis in myocardial infarction frame count in patients with stress (tako-tsubo) cardiomyopathy and comparison to those in patients with ST-elevation anterior wall myocardial infarction. Am J Cardiol 2008; 101:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/50\">",
"      Dib C, Asirvatham S, Elesber A, et al. Clinical correlates and prognostic significance of electrocardiographic abnormalities in apical ballooning syndrome (Takotsubo/stress-induced cardiomyopathy). Am Heart J 2009; 157:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/51\">",
"      Eitel I, Behrendt F, Schindler K, et al. Differential diagnosis of suspected apical ballooning syndrome using contrast-enhanced magnetic resonance imaging. Eur Heart J 2008; 29:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/52\">",
"      Hoyt J, Lerman A, Lennon RJ, et al. Left anterior descending artery length and coronary atherosclerosis in apical ballooning syndrome (Takotsubo/stress induced cardiomyopathy). Int J Cardiol 2010; 145:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/53\">",
"      Hanna M, Finkelhor RS, Shaw WF, Bahler RC. Extent of right and left ventricular focal wall-motion abnormalities in differentiating transient apical ballooning syndrome from apical dysfunction as a result of coronary artery disease. J Am Soc Echocardiogr 2007; 20:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/54\">",
"      Elesber AA, Prasad A, Bybee KA, et al. Transient cardiac apical ballooning syndrome: prevalence and clinical implications of right ventricular involvement. J Am Coll Cardiol 2006; 47:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/55\">",
"      Haghi D, Athanasiadis A, Papavassiliu T, et al. Right ventricular involvement in Takotsubo cardiomyopathy. Eur Heart J 2006; 27:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30745/abstract/56\">",
"      Elesber AA, Prasad A, Lennon RJ, et al. Four-year recurrence rate and prognosis of the apical ballooning syndrome. J Am Coll Cardiol 2007; 50:448.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3494 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-124.240.187.80-5DB13EDD60-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30745=[""].join("\n");
var outline_f30_1_30745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Physical or emotional stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Right ventricular involvement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      General therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hypotension and shock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Without left ventricular outflow tract obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - With left ventricular outflow tract obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9872698\">",
"      Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3494\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3494|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/59/4027\" title=\"table 1\">",
"      Killip classification of acute MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26952?source=related_link\">",
"      Cardiac complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/42/5802?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/35/8759?source=related_link\">",
"      Clinical syndromes of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/23/5497?source=related_link\">",
"      Left ventricular thrombus after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/55/10105?source=related_link\">",
"      Medical therapy in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/6/35938?source=related_link\">",
"      Patient information: Stress-induced cardiomyopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28600?source=related_link\">",
"      Types and pathophysiology of obstructive hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_1_30746="Agents affecting the 5-lipoxygenase pathway in the treatment of asthma";
var content_f30_1_30746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/1/30746/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30746/contributors\">",
"     Marc Peters-Golden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/1/30746/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30746/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30746/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/1/30746/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/1/30746/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/1/30746/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 5-lipoxygenase (5-LO) pathway is a series of biochemical reactions in which arachidonic acid, a component of membrane phospholipids, is transformed into pro-inflammatory mediators called leukotrienes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Leukotrienes possess diverse biological actions and are increasingly implicated in a variety of disease states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several lines of evidence support the role of leukotrienes in the pathogenesis of asthma, and agents with the capacity to inhibit the synthesis or action of leukotrienes are used in the treatment of asthma. Such agents represent the first new class of asthma medications to be introduced since inhaled glucocorticoids (inhaled GC), and the first to target a specific type of mediator.",
"   </p>",
"   <p>",
"    This topic reviews the evidence for the involvement of leukotrienes in asthma and the use of anti-leukotriene agents in the management of asthma. Recommendations for the treatment of asthma, incorporating the use of these and other therapies, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LEUKOTRIENE SYNTHESIS AND BIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;To understand the mechanisms of action of the anti-leukotriene agents, it is helpful to review briefly leukotriene synthesis and biology. Leukotrienes are synthesized within various types of leukocytes in response to activation of these cells. Upon activation, intracellular calcium concentrations rise, causing the enzyme 5-LO to translocate from soluble cytosolic or intranuclear pools to the perinuclear membrane. Here, it associates with the helper protein, 5-LO activating protein (FLAP) (",
"    <a class=\"graphic graphic_figure graphicRef75064 \" href=\"mobipreview.htm?25/55/26495\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FLAP is thought to \"present\" substrate arachidonate derived from membrane phospholipids to 5-LO, permitting it to catalyze the formation of an unstable intermediate known as leukotriene A4 (LTA4). This intermediate can then be transformed into two different classes of leukotrienes, cysteinyl leukotrienes (cysLTs) and leukotriene B4 (LTB4).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cysteinyl leukotrienes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cysteinyl leukotrienes are LTC4 and its derivatives, LTD4 and LTE4. CysLTs are the predominant class of leukotrienes synthesized by eosinophils and mast cells, two cell types that are prominent in asthmatic inflammation. CysLTs can also be produced by basophils and macrophages.",
"   </p>",
"   <p>",
"    LTC4 is generated by the conjugation of LTA4 with reduced glutathione (the tripeptide glu-gly-cys) by LTC4 synthase (",
"    <a class=\"graphic graphic_figure graphicRef75064 \" href=\"mobipreview.htm?25/55/26495\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. LTC4 is exported to the extracellular microenvironment through the action of a specific membrane transporter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Once in the extracellular microenvironment, LTC4 is rapidly converted to LTD4 and then LTE4 by sequential removal of the glutamic acid and then the glycine residues.",
"   </p>",
"   <p>",
"    CysLTs and their metabolites can be measured in various biological fluids, including plasma, urine, bronchoalveolar lavage, sputum, and exhaled breath condensate. However, these assays have a number of limitations, and are rarely performed outside of investigational settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/9\">",
"     9",
"    </a>",
"    ]. Measurement of leukotrienes is complicated by their inherent instability and the fact that synthesis may occur in brief bursts. Thus, their detection following synthesis may be limited to specific windows of time. One means of assessing leukotriene production is the measurement of urinary levels of the terminal metabolite, LTE4, which reflects total body cysLT production over the interval since the bladder was last emptied. The sensitivity of this approach is limited, however, as only a small percentage of exogenously administered cysLT can be recovered in the urine as LTE4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dihydroxy leukotrienes",
"    </span>",
"    &nbsp;&mdash;&nbsp;LTB4 is the only known member of a second class of leukotrienes, the dihydroxy leukotrienes. LTB4 arises from the hydrolysis of LTA4 by LTA4 hydrolase (",
"    <a class=\"graphic graphic_figure graphicRef75064 \" href=\"mobipreview.htm?25/55/26495\">",
"     figure 1",
"    </a>",
"    ). It is the major leukotriene product of neutrophils, and is also synthesized by macrophages. Once formed, LTB4 is also actively transported out of the source cell.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Variations in leukotriene synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Output of the leukotriene biosynthetic pathway may be influenced by both genetic and acquired factors. Enzyme deficiencies are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/11\">",
"     11",
"    </a>",
"    ]. However, various polymorphisms have been identified in either the coding or the promoter regions of 5-LO, FLAP, LTA4 hydrolase, and LTC4 synthase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Such polymorphisms have been associated in some studies with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -induced asthma or aspirin-exacerbated respiratory disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/15\">",
"     15",
"    </a>",
"    ]. Other factors, such as numerous cytokines, endotoxin, and the adipokine leptin, can result in variations in leukotriene synthesis by modulating the expression or activity of leukotriene-forming enzymes. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Patient characteristics that predict responsiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Leukotriene receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukotrienes act by binding to seven transmembrane spanning G protein-coupled receptors, which are found on multiple cell types, including inflammatory cells such as neutrophils, basophils, and eosinophils, as well as structural cells such as glandular epithelium, endothelial cells, and smooth muscle cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Receptors for cysLTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cysLTs bind to the cognate receptors CysLT1 and CysLT2 (",
"    <a class=\"graphic graphic_figure graphicRef75064 \" href=\"mobipreview.htm?25/55/26495\">",
"     figure 1",
"    </a>",
"    ). The actions of the cysLTs upon binding to CysLT1, in particular, are believed to be central to the pathogenesis of asthma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CysLT1 receptor mediates pro-asthmatic actions such as sustained bronchoconstriction, mucus secretion, and edema. The order of potency for cysLT binding at cysLT1 is LTD4&gt;LTC4&gt;&gt;LTE4. Two selective cysLT1 antagonists are currently available for the treatment of asthma. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Anti-leukotriene agents'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      As with the leukotriene-forming enzymes, the cysLT receptors are also subject to regulation. As an example, cysLT1 receptors in nasal inflammatory leukocytes are increased in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      -sensitive patients with chronic rhinosinusitis (with and without nasal polyposis) compared to non-aspirin-sensitive asthmatics, and are down-regulated after aspirin desensitization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=see_link\">",
"       \"Aspirin exacerbated respiratory disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The CysLT2 receptor does not have a known role in bronchoconstriction, although it may contribute to inflammation and edema formation by its actions on leukocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/17\">",
"       17",
"      </a>",
"      ] and vascular endothelium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/18,19\">",
"       18,19",
"      </a>",
"      ], respectively. No selective antagonists are currently available for CysLT2.",
"     </li>",
"     <li>",
"      It has long been known that neither cysLT1 nor cysLT2 has much affinity for LTE4, the final metabolite of all cysLTs. Yet, this stable metabolite is present in biological samples at high concentrations and inhaled LTE4 has both pro-inflammatory and bronchoconstrictor activity, raising the possibility of an additional LTE4 receptor. In mouse models, the purinergic receptor P2Y12 is necessary for LTE4 to promote eosinophilic inflammation and bronchial hyperresponsiveness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/20\">",
"       20",
"      </a>",
"      ]. If this or other receptors, which are not targeted by the cysLT1 antagonists (ie,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      , pranlukast,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      ), prove to be relevant in humans, they will likely become a target for novel drug development.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Receptors for LTB4",
"    </span>",
"    &nbsp;&mdash;&nbsp;LTB4 binds to BLT1 and BLT2 (",
"    <a class=\"graphic graphic_figure graphicRef75064 \" href=\"mobipreview.htm?25/55/26495\">",
"     figure 1",
"    </a>",
"    ). The biological effects of LTB4 are largely mediated by BLT1, a receptor that is upregulated differentially in response to stimuli such as LPS and tumor necrosis factor-alpha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Binding of LTB4 to BLT1 results in recruitment of neutrophils and eosinophils. BLT1 has also been implicated in recruitment of mast cell progenitors, as well as CD4+ and CD8+ T-lymphocytes, and CD8+ T-cells that express BLT1 have been identified in the BAL of asthmatic subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/25\">",
"     25",
"    </a>",
"    ]. Animal models have implicated the",
"    <span class=\"nowrap\">",
"     LTB4/BLT1",
"    </span>",
"    pathway in the development of allergic responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BLT2 binds LTB4 with lower affinity, and also binds other lipoxygenase and cyclooxygenase products. Its role in the asthmatic response is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LEUKOTRIENES IN ASTHMA PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several lines of evidence suggest that cysLTs contribute significantly to the pathogenesis of asthma. CysLTs are best known for their ability to induce smooth muscle contraction and protracted bronchoconstriction. This effect led to an early description of cysLTs as the \"slow reacting substance of anaphylaxis.\" As mentioned previously, the role of LTB4 in asthma is less well understood, but appears to be less central.",
"   </p>",
"   <p>",
"    An important characteristic of cysLT synthesis is its rapidity: resident leukocytes can synthesize cysLTs within minutes. Moreover, subsequent waves of cysLT generation can occur as leukocytes are recruited during a late-phase response, and as pro-inflammatory cytokines further upregulate expression of enzymes involved in their synthesis and that of their cognate receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Role of cysLTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;CysLTs can induce many of the abnormalities seen in both acute and chronic asthma. Actions of cysLTs include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction of smooth muscle contraction and protracted bronchoconstriction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Promotion of bronchovascular leakage and mucous gland secretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Promotion of leukocyte infiltration and stimulation of these cells to produce a variety of pro-inflammatory cytokines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Stimulation of airway smooth muscle cells and fibroblasts to proliferate, suggesting a possible role in airway remodeling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Asthmatics, as a group, produce higher levels of cysLTs than non-asthmatics at baseline. Levels of sputum cysLTs correlate with asthma severity in adults and the daily levels of urinary LTE4 were inversely associated with pulmonary function in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -sensitive asthma tend to have the highest levels of cysLT overproduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leukotriene levels in subjects with asthma increase further during exercise, or during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or allergen challenge in patients specifically sensitive to these triggers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Elevated levels of cysLT metabolites were detectable in over two-thirds of patients presenting for the emergency treatment of asthma exacerbations (",
"    <a class=\"graphic graphic_figure graphicRef68872 \" href=\"mobipreview.htm?0/36/589\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Role of LTB4",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of LTB4 in inflammation is different from that of the cysLTs; LTB4 is not known to participate in bronchospasm. Its best described role is that of a leukocyte chemoattractant, and it may be relevant to asthma pathogenesis through recruitment of neutrophils, eosinophils, mast cell precursors, and CD4+ and CD8+ T-lymphocytes. Severe asthma is more likely to be characterized by neutrophilic inflammation that is relatively refractory to glucocorticoids. The contribution of LTB4 in this specific phenotype has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Choice of anti-leukotriene agent'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36278?source=see_link\">",
"     \"Severe asthma: Evidence for heterogeneity of the disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANTI-LEUKOTRIENE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecules that inhibit leukotriene formation or action are commonly referred to as anti-leukotriene agents or leukotriene modifiers (",
"    <a class=\"graphic graphic_figure graphicRef75064 \" href=\"mobipreview.htm?25/55/26495\">",
"     figure 1",
"    </a>",
"    ). These terms are used interchangeably.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Available agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, three leukotriene modifying agents are available for the treatment of asthma (",
"    <a class=\"graphic graphic_table graphicRef77367 \" href=\"mobipreview.htm?20/12/20683\">",
"     table 1",
"    </a>",
"    ). Availability in other countries varies, as specified below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"       Zafirlukast",
"      </a>",
"      (Accolate&reg;) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      (Singulair&reg;) are antagonists of the action of cysLTs at the cysLT1 receptor. Pranlukast, available in Japan, is another cysLT1 receptor antagonist. In most of Europe, only montelukast is available.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"       Zileuton",
"      </a>",
"      (Zyflo&reg;) is an inhibitor of the catalytic activity of 5-LO and thus inhibits the formation of both the cysLTs and LTB4. This agent is only available in the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Currently, all of these agents are administered orally.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     Montelukast",
"    </a>",
"    is administered once daily,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    and pranlukast twice daily, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    regular formulation four times daily and controlled release formulation twice daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/38\">",
"     38",
"    </a>",
"    ]. Zileuton is approved in the United States for use in children 12 years and older, zafirlukast, for use in children older than five years and montelukast, in children older than one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of adverse effects have been described in small numbers (&le;2 percent) of people receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    , including anaphylaxis, angioedema, dizziness, dyspepsia, muscle weakness, and elevated transaminases.",
"   </p>",
"   <p>",
"    Postmarketing surveillance has found a few instances of suicidal thinking, suicide, and behavior or mood changes among patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    . However, a scientific review of clinical trial data requested by the Food and Drug Administration (FDA) did not find an increase in suicidal ideation in subjects taking montelukast compared with those on placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/39\">",
"     39",
"    </a>",
"    ]. A nested case-control study of insurance claims data found that current use of any leukotriene modifying agent was not associated with increased risk of a suicide attempt, but rather a slight trend in the opposite direction (adjusted OR 0.70, 95% CI 0.36-1.39) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition, a separate review of clinical trial data found no overall increase in behavior-related adverse events among subjects taking montelukast compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/41\">",
"     41",
"    </a>",
"    ]. It should be noted that depression and suicidality are more common in patients with asthma than in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/42\">",
"     42",
"    </a>",
"    ]. Professional societies have advised, pending further information, that patients do not need to discontinue montelukast unless they develop mood disturbance or suicidal ideation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    include headache, dyspepsia, myalgias, leukopenia, elevated transaminases, sleep disorders and behavior changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/44\">",
"     44",
"    </a>",
"    ]. Use in patients with a history of liver disease or substantial alcohol consumption should be avoided. The manufacturer recommends monitoring serum alanine aminotransferase (ALT) monthly for the first three months, every two to three months for the rest of the first year, and periodically thereafter. Drug interactions are possible; zileuton inhibits cytochrome CYP1A2 and has a mild interaction with CYP1A2, 2C9, 3A4. For this reason,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    dosing may have to be adjusted downwards.",
"   </p>",
"   <p>",
"    A Churg-Strauss-like syndrome develops as a rare complication in steroid-dependent asthmatics treated with anti-leukotriene agents. In most instances, this occurs following tapering of the oral glucocorticoid dose, suggesting that underlying Churg-Strauss syndrome may be unmasked by glucocorticoid withdrawal, rather than being caused by the drugs themselves. However, at least one analysis argues against dismissing a possible causal relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/45\">",
"     45",
"    </a>",
"    ]. The pathogenesis of Churg-Strauss syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\", section on 'Leukotriene modifying agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL USE IN ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-leukotriene agents were initially studied for their ability to reduce asthmatic responses to bronchoprovocation challenge. Physiologic findings of airflow obstruction induced by exercise, allergen,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and the pollutant sulfur dioxide were all substantially attenuated by pretreatment with either cysLT1 antagonists or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/46-50\">",
"     46-50",
"    </a>",
"    ]. In the case of allergen-induced asthmatic reactions, both early- and late-phase bronchoconstrictor responses were attenuated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/51\">",
"     51",
"    </a>",
"    ]. These results prompted subsequent trials demonstrating that these agents were also useful in long-term asthma control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Use as first-line controller therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controller therapies for asthma currently include two groups of medications: glucocorticoids and anti-leukotriene agents. Both have beneficial effects on clinical symptoms and lead to decreases in markers of inflammation, although these properties have been best characterized for inhaled GCs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Compared to placebo",
"    </span>",
"    &nbsp;&mdash;&nbsp;In randomized placebo-controlled trials, the utility of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    as first-line controller monotherapy has been examined in adult patients with stable mild and moderate persistent asthma. Each provides a superior effect to placebo in the following outcome measures (",
"    <a class=\"graphic graphic_figure graphicRef54679 \" href=\"mobipreview.htm?12/62/13294\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/38,46,52-54\">",
"     38,46,52-54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung function (typically resulting in a 10 to 15 percent improvement in forced expiratory volume in the first second (FEV1) and improvement in measures of distal lung function)",
"     </li>",
"     <li>",
"      Daytime and nighttime asthma symptoms and asthma-specific quality of life",
"     </li>",
"     <li>",
"      Need for rescue beta-agonist therapy",
"     </li>",
"     <li>",
"      Frequency of asthma exacerbations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No evidence of tolerance to these beneficial effects has been noted during treatment for periods up to two years.",
"   </p>",
"   <p>",
"    The cysLT1 antagonists",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    are also effective in children. Specifically, children with moderate persistent asthma who were treated with montelukast experienced improved lung function at baseline, decreased asthma symptoms, increased asthma-specific quality of life, and decreased need for asthma rescue medication use as compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/47,48,55\">",
"     47,48,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Compared to inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although initially developed for their bronchodilatory actions, leukotriene modifiers do exert antiinflammatory effects, such as reducing the numbers of circulating and sputum eosinophils, exhaled nitric oxide, and nonspecific bronchial hyperresponsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. In general, however, the magnitude of such anti-inflammatory effects is less than those of glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical trials comparing these two classes of controller agents, inhaled GC usually have proven superior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/59\">",
"     59",
"    </a>",
"    ]. However, the nature and magnitude of the differences between these treatments are variable. In some of these trials, inhaled GCs were superior in all endpoints examined, while in others, they were superior only in some outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. A few studies have found no significant differences between the two drug classes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. Comparative studies typically utilize mean group data to compare the two active agents, a practice which obscures interpatient variation and limits extrapolation to clinical practice. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Heterogeneity of response to controller therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Studies comparing these two types of therapies also reveal a typical pattern, in which the superiority of inhaled GC over leukotriene modifiers in improving lung function measures is greater than the advantage of inhaled GC in improving patient-centered measures of asthma control (symptoms, quality of life, or resource utilization) or of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     \"Real-world\" issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;While efficacy comparisons generally favor inhaled GC over anti-leukotrienes, real-world effectiveness also depends upon other factors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is well known that patient adherence to inhaled GC is suboptimal, and most studies have demonstrated superior patient adherence to once-daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      than to inhaled GC in both children and adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/64,65,69,70\">",
"       64,65,69,70",
"      </a>",
"      ]. The superior adherence to montelukast may explain its comparable beneficial effects on asthma control to those of inhaled GC in some \"real-world\" studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. Despite the importance of this issue in clinical practice, it is largely circumvented in clinical trials by having study coordinators provide frequent reminders to patients and by excluding those patients whose adherence (as documented by electronic monitors built into the inhaler devices) is deemed insufficient. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12789?source=see_link\">",
"       \"Enhancing patient adherence to asthma therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is also apparent that primary care clinicians tend to under-prescribe inhaled GC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, no matter how efficacious inhaled GC may be, their utility in real-world settings is limited by inadequate prescribing and adherence. While not the preferred choice based upon efficacy in study populations, anti-leukotrienes may be considered a reasonable first-line controller agent for patients who either will not take or cannot tolerate inhaled GC. Validation of this approach is supported by a so-called &ldquo;pragmatic&rdquo; trial conducted in 306 patients managed in primary care practices, in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    was demonstrated to be comparable to inhaled GC as a first-line controller therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Additive benefit with inhaled GC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-leukotrienes may provide modest additive benefit when used as adjunctive therapy with inhaled GC, although differences among patients in response to combined therapy have not been studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies support the conclusion that glucocorticoids have minimal effects on leukotriene biosynthesis or responses, and persistent overproduction of leukotrienes has been repeatedly documented in patients on substantial doses of inhaled GC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/74-79\">",
"     74-79",
"    </a>",
"    ]. A combination of the two types of medications, therefore, may afford complementary anti-inflammatory and bronchoprotective actions.",
"   </p>",
"   <p>",
"    Two clinical questions have been addressed regarding the additivity between inhaled GC and anti-leukotriene agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Does addition of an anti-leukotriene improve asthma control in a patient whose control is inadequate on inhaled GC alone?",
"     </li>",
"     <li>",
"      Does addition of an anti-leukotriene, in a patient with controlled asthma, allow control to be maintained despite reducing the dose of inhaled GC (ie, a steroid-sparing effect)?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first question has been addressed in both adults and children with double blind, controlled trials. In one adult study, addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    200 mcg twice daily improved lung function and symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/80\">",
"     80",
"    </a>",
"    ]. In another, addition of montelukast to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    (800 mcg daily) yielded a degree of improvement similar to doubling the dose of budesonide (ie, increased lung function and decreased symptoms, rescue bronchodilator use, exacerbations, and peripheral blood eosinophils) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/81\">",
"     81",
"    </a>",
"    ]. In children, montelukast added to inhaled GC resulted in more rescue-free days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/72\">",
"     72",
"    </a>",
"    ]. However, two studies failed to find an improvement in asthma events, lung function, or rescue bronchodilator use when montelukast was added to prior inhaled GC in adults with inadequate asthma control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies note that subjective measures or indices of inflammation are more sensitive to the beneficial effects of add-on leukotriene modifier than are lung function measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/68,76\">",
"     68,76",
"    </a>",
"    ]. A possible explanation is that the intrinsic bronchodilatory actions of anti-leukotriene drugs may be difficult to discern when patients' lung function has already improved from inhaled GC.",
"   </p>",
"   <p>",
"    Examining possible steroid-sparing effects requires the addition of an anti-leukotriene agent or placebo to patients receiving inhaled GC, followed by a scheduled, stepwise tapering of inhaled GC dosage. Superior asthma control with addition of anti-leukotriene agents during tapering of inhaled GC has been demonstrated in adults in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/84-87\">",
"     84-87",
"    </a>",
"    ]. Another adult study found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    was only partially able to mitigate the consequences of a 75 percent reduction in inhaled glucocorticoid dosage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/88\">",
"     88",
"    </a>",
"    ]. In a pediatric study, addition of montelukast tended to provide greater symptomatic control during tapering than did placebo, but the difference did not reach statistical significance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/72\">",
"     72",
"    </a>",
"    ]. Thus, the effectiveness of anti-leukotrienes used in this manner may be less predictable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Compared to long-acting beta-agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who remain symptomatic despite inhaled GC therapy, treatment guidelines recommend the addition of a second agent from a different therapeutic class. Several double-blind, placebo controlled studies have compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    to long-acting beta agonists (LABAs) in this setting. Predictably, reduction in blood markers of inflammation (eg, eosinophilia) favored montelukast over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    , while improvements in lung function favored salmeterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. The weight of evidence supports the conclusion that addition of a LABA tends to result in superior asthma control and fewer exacerbations compared to the addition of montelukast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/93\">",
"     93",
"    </a>",
"    ]. Similar results have been observed in comparisons of salmeterol and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all studies comparing the effects of adding anti-leukotriene agents or LABAs to inhaled GC therapy have concluded that LABAs are better. Comparable benefit was seen in some, particularly in the outcome of reduced rates of exacerbation, suggesting that both are useful in this regard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/66,89,90\">",
"     66,89,90",
"    </a>",
"    ]. As noted above, in a &ldquo;pragmatic&rdquo; trial in primary care practices,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    was found to be comparable to a LABA as add-on therapy for patients inadequately controlled on inhaled GC alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/66\">",
"     66",
"    </a>",
"    ]. In addition, the performance of LABAs must be weighed against their possible adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Heterogeneity of response to controller therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals differ in their response to anti-leukotriene agents, a phenomenon that has become widely appreciated. It is less recognized, however, that individual patients also vary in their responses to inhaled GC and beta agonists, as well.",
"   </p>",
"   <p>",
"    The heterogeneity observed in the response to both inhaled GC and anti-leukotriene agents was well-illustrated in a large, multicenter, double-blinded trial of 895 patients with varying severity of asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/61\">",
"     61",
"    </a>",
"    ]. Subjects were randomly assigned to receive once-daily oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    , inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    , or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/61\">",
"     61",
"    </a>",
"    ]. Beclomethasone was significantly superior to montelukast in its capacity to improve objective measures of lung function as measured by average responses; however, examination of the distribution of responses of individuals in the population was revealing. The difference in the mean response was driven by a small fraction of patients with a substantial improvement in lung function (&gt;40 percent improvement in FEV1) with beclomethasone, combined with a small fraction of patients receiving montelukast who failed to respond at all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In randomized controlled trials (RCTs) of leukotriene modifiers, symptom-based outcomes appear to be favorably affected by the addition of antileukotriene agents in perhaps 60 to 80 percent of patients, whereas improvements in lung function are noted in a lower proportion of subjects (perhaps 35 to 50 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All classes of asthma medications exhibit heterogeneity in their efficacy among individual patients. The proportion of patients who are anti-leukotriene \"non-responders\" (often judged by clinicians to be as high as 50 percent) exceeds that observed with inhaled GC, because leukotriene modifiers target a single class of mediators while the anti-inflammatory effects of inhaled GC are broad. In addition, the proportion of non-responders is dependent upon the endpoints chosen, as certain endpoints are more or less reflective of the mechanism of a given agent. The reasons for this heterogeneity of response are explored further in the next section. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Patient characteristics that predict responsiveness'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Patient characteristics that predict responsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;In view of this heterogeneity, it would be helpful to identify characteristics that might predict responsiveness to anti-leukotrienes. Potential determinants can be grouped into three categories: biomarkers, genotypic markers, and demographic or clinical characteristics of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biomarkers that reflect leukotriene production are an active area of investigation, although these markers are not currently used in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/95-98\">",
"     95-98",
"    </a>",
"    ]. One obvious candidate biomarker is the degree of leukotriene overproduction itself. One study found that mean levels of ex vivo cysLT production by stimulated whole blood leukocytes were higher in patients deemed to be responders to a cysLT1 antagonist than in non-responders, but the sensitivity and specificity of this parameter were inadequate to guide clinical decision-making [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies examining urinary LTE4 levels as a predictor of response to anti-leukotriene drugs have yielded variable results. For example, some studies in patients with moderate persistent asthma or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    sensitive asthma have shown no relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. An inverse relationship was reported between urinary LTE4 and response to a cysLT1 antagonist in another study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/99\">",
"     99",
"    </a>",
"    ]. In the largest series reported (albeit still only comprising 48 patients), a correlation among mild-moderate asthmatics between urinary LTE4 and responsiveness was observed, but again the sensitivity and specificity were inadequate to be clinically useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H720908755\">",
"    <span class=\"h3\">",
"     Genotypic markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphisms in genes encoding 5-LO and LTC4 synthase have been suggested to predict responsiveness to anti-leukotriene drugs. Variants of the 5-LO promoter are associated with diminished responses to a 5-LO inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/101\">",
"     101",
"    </a>",
"    ]. However, these variants occur in fewer than 10 percent of asthmatics and therefore cannot explain much of the observed non-responsiveness to leukotriene modifiers. A polymorphism in the LTC4 synthase gene is more common, occurring in approximately 20 to 40 percent of asthmatics. A positive relationship between this variant allele and clinical response to anti-leukotriene drugs has been reported in two studies, although not in a third [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/96,102,103\">",
"     96,102,103",
"    </a>",
"    ]. As there is uncertainty regarding both the relationship between the degree of leukotriene overproduction and response to leukotriene modifiers (discussed above) as well as the precise impact of these variant genotypes on leukotriene synthetic capacity, it is not clear whether the possible predictive value of these variant genotypes is actually explained by altered leukotriene synthetic capacity.",
"   </p>",
"   <p>",
"    Minimal data exist on the possible role of variant leukotriene receptors as determinants of responsiveness to these drugs; one study found that variants in the cysLT2 gene were associated with greater responsiveness to a cysLT1 antagonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/104\">",
"     104",
"    </a>",
"    ]. This puzzling observation can perhaps be explained by in vitro studies demonstrating that cysLT2 can interact with and attenuate responses to cysLT1 ligation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variation in drug absorption is another possible explanation for variability of response to leukotriene modifiers. Genetic variation in the transporter gene SLCO2B1 (Solute Carrier Organic Anion Transporter family, member 2B1, MIM 604988) has been associated with variation in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    plasma levels and with variability of response to montelukast among patients with asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/106\">",
"     106",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of pharmacogenomics\", section on 'Drug transport'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Clinical characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several patient characteristics may correlate in group data with greater responsiveness to leukotriene modifiers, as discussed below. However, it is important to point out that substantial variability characterizes responses in each of these patient populations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      -sensitive asthma &ndash; As a group, patients with aspirin-sensitive asthma not only have the highest degrees of leukotriene overproduction, but also tend to benefit more dramatically when anti-leukotriene agents are added to inhaled",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oral glucocorticoids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/33,97,107\">",
"       33,97,107",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=see_link\">",
"       \"Aspirin exacerbated respiratory disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exercise-induced symptoms &ndash; Anti-leukotrienes are generally highly protective against exercise-induced bronchospasm.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"       Zileuton",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      all ameliorate exercise-induced bronchospasm to a similar degree [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     Montelukast",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    have been compared with respect to their capacity to inhibit exercise-induced bronchospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. On the third day of treatment, both agents had similar effects, but after four and eight weeks the effects of montelukast were sustained while those of salmeterol had waned. The combination of montelukast plus salmeterol was shown in one study to provide greater protection against exercise-induced bronchospasm than either agent alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Protection against exercise-induced bronchospasm with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    is detectable as early as two hours after a single oral dose and persists for up to 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/112\">",
"     112",
"    </a>",
"    ]. For patients who require specific pretreatment prior to exercise, regardless of whether they are on chronic controller therapy, a leukotriene modifier dosed two hours prior to exercise is a reasonable and effective alternative to pretreatment with short-acting beta-agonists and is now FDA approved for this indication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral URI-induced symptoms &ndash; There is abundant evidence that leukotrienes are generated during various viral respiratory infections, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      in children reduces the frequency of infection-associated exacerbations and ameliorates the symptoms of RSV-associated exacerbations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/113,114\">",
"       113,114",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other patient characteristics have been proposed, although their ability to predict a response to anti-leukotriene agents has not been convincingly demonstrated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children &ndash; On average, children may be more likely than adults to benefit from leukotriene modifier therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/115\">",
"       115",
"      </a>",
"      ]. In another study, younger children were more likely to benefit compared to older children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/116\">",
"       116",
"      </a>",
"      ]. Whether this might reflect a greater prevalence of symptoms triggered by viral URIs in young children remains to be determined.",
"     </li>",
"     <li>",
"      Symptoms triggered by air pollutants &ndash; Leukotrienes are overproduced upon respiratory tract exposure to pollutants, such as sulfur dioxide and particulates. CysLT1 antagonists reduce airway inflammation and bronchoconstrictor responses to both types of pollutants in laboratory challenge settings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/50,117,118\">",
"       50,117,118",
"      </a>",
"      ]. The specific utility of anti-leukotrienes in ameliorating or preventing pollutant-induced asthma has not been explored, however.",
"     </li>",
"     <li>",
"      Asthma severity &ndash; It is not clear whether asthma severity per se influences the comparative likelihood of a response to an anti-leukotriene agent versus an inhaled GC. One study suggested that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      was more likely to be inferior to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      in moderate-to-severe than in mild asthmatics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/119\">",
"       119",
"      </a>",
"      ]. However, significant benefit in all efficacy measures was noted in a group of 261 patients with severe persistent asthma who were inadvertently treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/120\">",
"       120",
"      </a>",
"      ]. It is our experience that severity alone is not particularly helpful in predicting response to a leukotriene modifier. However, we do not recommend using anti-leukotriene agents as monotherapy in moderate or severe persistent asthma.",
"     </li>",
"     <li>",
"      Allergic rhinitis &ndash; As allergic rhinitis coexists with asthma in many patients, and RCTs indicate that anti-leukotrienes have modest efficacy in allergic rhinitis, anti-leukotrienes may ameliorate both upper and lower airway disease. In a retrospective, uncontrolled, observational study of several thousand patients with both conditions, approximately 80 percent of patients reported meaningful improvement in both conditions with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/121\">",
"       121",
"      </a>",
"      ]. It has",
"      <strong>",
"       not",
"      </strong>",
"      been our experience, however, that patients with both conditions or patients with atopic triggers for their asthma are any more likely to benefit from leukotriene modifiers than are patients without concomitant allergic rhinitis or atopy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=see_link&amp;anchor=H25107466#H25107466\">",
"       \"Pharmacotherapy of allergic rhinitis\", section on 'Montelukast'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obesity &ndash; Obesity is associated with an increased relative risk and severity of asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/122-124\">",
"       122-124",
"      </a>",
"      ]. In a post-hoc analysis, asthma control days decreased with increasing body mass index in patients treated with either placebo or inhaled GC, while",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      efficacy was unaffected by body mass index [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/125\">",
"       125",
"      </a>",
"      ]. Greater relative benefit of montelukast in the obese has been suggested to reflect the fact that leptin, an adipocyte-derived hormone whose plasma levels parallel body mass index, positively regulates leukotriene levels in rodent models [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/126\">",
"       126",
"      </a>",
"      ]. Whether obesity is predictive of response to a leukotriene modifier has yet to be verified in prospective trials. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=see_link\">",
"       \"Physiology of leptin\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cigarette smoking &ndash; Cigarette smoking stimulates cysteinyl leukotriene production; urinary LTE4 is increased in a dose-dependent fashion in smokers. Furthermore, after non-smokers have smoked only six cigarettes, urinary LTE4 excretion increases two-fold within 12 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/127\">",
"       127",
"      </a>",
"      ]. One study showed that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      significantly increased morning peak flow in mild asthmatic smokers, but not in non-smokers, while",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      increased FEV1 in non-smokers, but not smokers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/128\">",
"       128",
"      </a>",
"      ]. Although the study was small, it raised the possibility that anti-leukotrienes may be more effective in smokers than non-smokers and inhaled GC may not be quite as effective in smokers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Choice of anti-leukotriene agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no efficacy data favoring either of the cysLT1 antagonists available in the United States (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    ) over the other (",
"    <a class=\"graphic graphic_table graphicRef77367 \" href=\"mobipreview.htm?20/12/20683\">",
"     table 1",
"    </a>",
"    ). However, montelukast is commonly preferred because it is once daily and can be taken at any time in relation to meals.",
"   </p>",
"   <p>",
"    In the first head-to-head comparison, patients with mild to moderate asthma on no other medications were assigned to take the 5-LO inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    , or the cysLT1 antagonist,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    , for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/129\">",
"     129",
"    </a>",
"    ]. Zileuton demonstrated slightly greater efficacy in improving peak flow and symptom scores than did montelukast, with comparable tolerability. This study supports the theoretical advantage of zileuton over the receptor antagonists, since it acts further \"upstream\" and inhibits production of all the cysLTs and other 5-LO metabolites including LTB4 (",
"    <a class=\"graphic graphic_figure graphicRef75064 \" href=\"mobipreview.htm?25/55/26495\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Dihydroxy leukotrienes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"     Zileuton",
"    </a>",
"    is available in two preparations: immediate release (Zyflo&reg;, 600 mg four times daily) and controlled release (Zyflo CR&reg;, 1200 mg twice daily). Both preparations require monitoring of liver function tests and have potential for drug interactions. We are aware of a number of anecdotal experiences with patients who clinically benefited from zileuton after failing cysLT1 antagonist therapy. Post hoc analysis of data from clinical trials suggests that zileuton has a greater impact in patients with more severe rather than milder airflow obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/130\">",
"     130",
"    </a>",
"    ]. Additional studies are needed to clarify whether a unique role exists for zileuton or for alternative leukotriene biosynthesis inhibitors, especially in patients with severe asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Duration of therapeutic trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;A therapeutic trial is necessary to assess the utility of an anti-leukotriene agent in any individual patient, since it is currently impossible to reliably predict responsiveness. As noted above, both objective and subjective parameters must be assessed in order to comprehensively gauge benefit.",
"   </p>",
"   <p>",
"    It is possible to see benefit as early as the first day of treatment. This likely reflects the intrinsic bronchodilator activity of anti-leukotrienes, and the fact that leukotriene overproduction at baseline contributes to increased bronchial tone. This has been reported for both adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/53,131,132\">",
"     53,131,132",
"    </a>",
"    ]. An anti-inflammatory effect, as judged by reductions in exhaled nitric oxide and bronchial hyperresponsiveness, has been observed within one and two weeks of initiation of therapy, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/57,133\">",
"     57,133",
"    </a>",
"    ]. Even more gradual is the improvement in lung function and symptoms, which can occur over several weeks to months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/67,89\">",
"     67,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The kinetics of improvement for different endpoints within individual patients have not been studied. Thus, it is our practice to employ a one to two month trial, regardless of which agent is selected and whether the leukotriene modifier is being utilized as first-line or add-on therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Use in acute asthma exacerbations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of an anti-leukotriene agent to inhaled beta-agonists and systemic glucocorticoids has been shown to be beneficial in the treatment of asthma exacerbations in the emergency department [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/1/30746/abstract/134,135\">",
"     134,135",
"    </a>",
"    ]. The use of anti-leukotriene agents in this setting is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukotrienes are pro-inflammatory mediators involved in the pathogenesis of asthma. Anti-leukotriene medications block the synthesis or actions of leukotrienes and are useful in managing asthma in both children and adults. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cysteinyl leukotrienes (cysLTs), LTC4, LTD4, and LTE4, are synthesized by eosinophils and mast cells, two cell types that are prominent in asthmatic inflammation. Upon binding to the CysLT1 receptor, the cysLTs mediate pro-asthmatic effects such as sustained bronchoconstriction, mucus secretion, and edema. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Leukotriene synthesis and biology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anti-leukotriene agents either inhibit the formation of leukotrienes, or block their interaction with the receptor (",
"      <a class=\"graphic graphic_figure graphicRef75064 \" href=\"mobipreview.htm?25/55/26495\">",
"       figure 1",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/54/20325?source=see_link\">",
"       Zafirlukast",
"      </a>",
"      (Accolate&reg;) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      (Singulair&reg;) antagonize the action of cysLTs at the cysLT1 receptor.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/33/17940?source=see_link\">",
"       Zileuton",
"      </a>",
"      (Zyflo&reg;, ZyfloCR&reg;) inhibits the formation of leukotrienes. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Available agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Use in asthma management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-leukotriene agents can be effective as monotherapy in the treatment of mild to moderate persistent asthma. These agents increase lung function and symptom-related quality of life, and decrease the frequency of exacerbations and the need for symptom-relieving beta-agonist medications. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Compared to placebo'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mean efficacy of anti-leukotriene agents is lower than that of inhaled glucocorticoids, so anti-leukotriene agents are not considered first line therapy for mild to moderate persistent asthma. However, leukotriene modifiers are a reasonable alternative for patients who cannot tolerate, are unwilling to take, or who have not responded to inhaled glucocorticoids. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Use as first-line controller therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In some but not all studies, anti-leukotriene agents may provide a modest degree of additive benefit for patients with moderate or severe persistent asthma whose disease is inadequately controlled on inhaled glucocorticoids alone. Anti-leukotriene agents added to inhaled glucocorticoid therapy may also be steroid-sparing, although this effect was not consistently found in all studies. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Additive benefit with inhaled GC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The addition of a long-acting beta-agonist (LABA), rather than an antileukotriene agent, is another option for treating asthma that is inadequately controlled with inhaled GC. Although a LABA will generally provide superior improvement in lung function, the advantages over anti-leukotriene agents in other endpoints are more modest and must be weighed against the possible adverse effects of beta-agonists. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Compared to long-acting beta-agonists'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/19/16698?source=see_link\">",
"       \"Beta agonists in asthma: Controversy regarding chronic use\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Individuals differ in their response to anti-leukotriene agents. Some patients respond dramatically, although up to 50 percent show no response at all. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Heterogeneity of response to controller therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In group data, clinical characteristics that predict a favorable response to anti-leukotriene agents include the presence of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      -sensitive asthma, exercise-induced symptoms, and exacerbations triggered by viral infections. However, no clinical characteristics are capable of predicting responsiveness in individual patients. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Patient characteristics that predict responsiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A therapeutic trial is necessary to assess the utility of an anti-leukotriene agent in any individual patient. We suggest a one to two month trial, regardless of which agent is selected and whether the leukotriene modifier is being utilized as first-line or add-on therapy. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Duration of therapeutic trials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/1\">",
"      Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/2\">",
"      O'Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997; 127:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/3\">",
"      Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007; 357:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/4\">",
"      Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004; 350:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/5\">",
"      Dixon RA, Diehl RE, Opas E, et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/6\">",
"      Lam BK, Penrose JF, Freeman GJ, Austen KF. Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4. Proc Natl Acad Sci U S A 1994; 91:7663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/7\">",
"      Austen KF, Maekawa A, Kanaoka Y, Boyce JA. The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol 2009; 124:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/8\">",
"      Lam BK, Owen WF Jr, Austen KF, Soberman RJ. The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils. J Biol Chem 1989; 264:12885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/9\">",
"      Kumlin M. Measurement of leukotrienes in humans. Am J Respir Crit Care Med 2000; 161:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/10\">",
"      Kumlin M. Measurements of leukotrienes in the urine: strategies and applications. Allergy 1997; 52:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/11\">",
"      Mayatepek E. Leukotriene C4 synthesis deficiency: a member of a probably underdiagnosed new group of neurometabolic diseases. Eur J Pediatr 2000; 159:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/12\">",
"      In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/13\">",
"      Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/14\">",
"      Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006; 38:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/15\">",
"      Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/16\">",
"      Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/17\">",
"      Mellor EA, Frank N, Soler D, et al. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R. Proc Natl Acad Sci U S A 2003; 100:11589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/18\">",
"      Beller TC, Maekawa A, Friend DS, et al. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice. J Biol Chem 2004; 279:46129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/19\">",
"      Hui Y, Cheng Y, Smalera I, et al. Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 2004; 110:3360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/20\">",
"      Paruchuri S, Tashimo H, Feng C, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 2009; 206:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/21\">",
"      Samuelsson B, Dahl&eacute;n SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/22\">",
"      Yokomizo T, Izumi T, Chang K, et al. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997; 387:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/23\">",
"      Yokomizo T, Kato K, Terawaki K, et al. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000; 192:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/24\">",
"      Qiu H, Johansson AS, Sj&ouml;str&ouml;m M, et al. Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4. Proc Natl Acad Sci U S A 2006; 103:6913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/25\">",
"      Gelfand EW, Dakhama A. CD8+ T lymphocytes and leukotriene B4: novel interactions in the persistence and progression of asthma. J Allergy Clin Immunol 2006; 117:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/26\">",
"      Taube C, Miyahara N, Ott V, et al. The leukotriene B4 receptor (BLT1) is required for effector CD8+ T cell-mediated, mast cell-dependent airway hyperresponsiveness. J Immunol 2006; 176:3157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/27\">",
"      Griffin M, Weiss JW, Leitch AG, et al. Effects of leukotriene D on the airways in asthma. N Engl J Med 1983; 308:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/28\">",
"      Johnson HG, Chinn RA, Chow AW, et al. Leukotriene-C4 enhances mucus production from submucosal glands in canine trachea in vivo. Int J Immunopharmacol 1983; 5:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/29\">",
"      Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006; 36:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/30\">",
"      Espinosa K, Boss&eacute; Y, Stankova J, Rola-Pleszczynski M. CysLT1 receptor upregulation by TGF-beta and IL-13 is associated with bronchial smooth muscle cell proliferation in response to LTD4. J Allergy Clin Immunol 2003; 111:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/31\">",
"      Green SA, Malice MP, Tanaka W, et al. Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation. Thorax 2004; 59:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/32\">",
"      Rabinovitch N, Zhang L, Gelfand EW. Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction. J Allergy Clin Immunol 2006; 118:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/33\">",
"      Antczak A, Montuschi P, Kharitonov S, et al. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002; 166:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/34\">",
"      Taylor GW, Taylor I, Black P, et al. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989; 1:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/35\">",
"      Sladek K, Dworski R, Fitzgerald GA, et al. Allergen-stimulated release of thromboxane A2 and leukotriene E4 in humans. Effect of indomethacin. Am Rev Respir Dis 1990; 141:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/36\">",
"      Drazen JM, O'Brien J, Sparrow D, et al. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992; 146:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/37\">",
"      Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997; 156:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/38\">",
"      Nelson H, Kemp J, Berger W, et al. Efficacy of zileuton controlled-release tablets administered twice daily in the treatment of moderate persistent asthma: a 3-month randomized controlled study. Ann Allergy Asthma Immunol 2007; 99:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/39\">",
"      Philip G, Hustad C, Noonan G, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009; 124:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/40\">",
"      Schumock GT, Stayner LT, Valuck RJ, et al. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study. J Allergy Clin Immunol 2012; 130:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/41\">",
"      Philip G, Hustad CM, Malice MP, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009; 124:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/42\">",
"      Druss B, Pincus H. Suicidal ideation and suicide attempts in general medical illnesses. Arch Intern Med 2000; 160:1522.",
"     </a>",
"    </li>",
"    <li>",
"     Joint statement on FDA investigation of Singulair from the AAAAI and ACAAI. https://aaaai.org/media/news_releases/2008/03/jointstatement.asp.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/44\">",
"      Watkins PB, Dube LM, Walton-Bowen K, et al. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma. Drug Saf 2007; 30:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/45\">",
"      Bibby S, Healy B, Steele R, et al. Association between leukotriene receptor antagonist therapy and Churg-Strauss syndrome: an analysis of the FDA AERS database. Thorax 2010; 65:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/46\">",
"      Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/47\">",
"      Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/48\">",
"      Pearlman DS, Ostrom NK, Bronsky EA, et al. The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr 1999; 134:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/49\">",
"      Nasser SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994; 49:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/50\">",
"      Lazarus SC, Wong HH, Watts MJ, et al. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 1997; 156:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/51\">",
"      Diamant Z, Grootendorst DC, Veselic-Charvat M, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999; 29:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/52\">",
"      Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med 1994; 150:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/53\">",
"      Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/54\">",
"      Kraft M, Cairns CB, Ellison MC, et al. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest 2006; 130:1726.",
"     </a>",
"    </li>",
"    <li>",
"     Anonymous. Package insert. 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/56\">",
"      Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999; 14:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/57\">",
"      Lee MY, Lai YS, Yang KD, et al. Effects of montelukast on symptoms and eNO in children with mild to moderate asthma. Pediatr Int 2005; 47:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/58\">",
"      Straub DA, Minocchieri S, Moeller A, et al. The effect of montelukast on exhaled nitric oxide and lung function in asthmatic children 2 to 5 years old. Chest 2005; 127:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/59\">",
"      Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012; 5:CD002314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/60\">",
"      Zeiger RS, Bird SR, Kaplan MS, et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005; 118:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/61\">",
"      Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/62\">",
"      Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005; 116:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/63\">",
"      Allen-Ramey FC, Duong PT, Riedel AA, et al. Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline. Ann Allergy Asthma Immunol 2004; 93:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/64\">",
"      Maspero JF, Due&ntilde;as-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 2001; 17:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/65\">",
"      Balkrishnan R, Nelsen LM, Kulkarni AS, et al. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis. J Asthma 2005; 42:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/66\">",
"      Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/67\">",
"      Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002; 110:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/68\">",
"      Currie GP, Lee DK, Haggart K, et al. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003; 167:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/69\">",
"      Stempel DA, Stoloff SW, Carranza Rosenzweig JR, et al. Adherence to asthma controller medication regimens. Respir Med 2005; 99:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/70\">",
"      Bukstein DA, Luskin AT, Bernstein A. \"Real-world\" effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003; 90:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/71\">",
"      Tan H, Sarawate C, Singer J, et al. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes. Mayo Clin Proc 2009; 84:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/72\">",
"      Phipatanakul W, Greene C, Downes SJ, et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol 2003; 91:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/73\">",
"      Ulrik CS, Diamant Z. Add-on montelukast to inhaled corticosteroids protects against excessive airway narrowing. Clin Exp Allergy 2010; 40:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/74\">",
"      Sladek K, Dworski R, Soja J, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/75\">",
"      Gyllfors P, Dahl&eacute;n SE, Kumlin M, et al. Bronchial responsiveness to leukotriene D4 is resistant to inhaled fluticasone propionate. J Allergy Clin Immunol 2006; 118:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/76\">",
"      Biernacki WA, Kharitonov SA, Biernacka HM, Barnes PJ. Effect of montelukast on exhaled leukotrienes and quality of life in asthmatic patients. Chest 2005; 128:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/77\">",
"      Wenzel SE. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 1997; 17:3S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/78\">",
"      Vachier I, Kumlin M, Dahl&eacute;n SE, et al. High levels of urinary leukotriene E4 excretion in steroid treated patients with severe asthma. Respir Med 2003; 97:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/79\">",
"      Severien C, Artlich A, Jonas S, Becher G. Urinary excretion of leukotriene E4 and eosinophil protein X in children with atopic asthma. Eur Respir J 2000; 16:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/80\">",
"      Baumgartner RA, Martinez G, Edelman JM, et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J 2003; 21:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/81\">",
"      Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003; 58:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/82\">",
"      Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001; 357:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/83\">",
"      American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007; 175:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/84\">",
"      L&ouml;fdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 1999; 319:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/85\">",
"      Riccioni G, Vecchia RD, Castronuovo M, et al. Tapering dose of inhaled budesonide in subjects with mild-to-moderate persistent asthma treated with montelukast: a 16-week single-blind randomized study. Ann Clin Lab Sci 2005; 35:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/86\">",
"      Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 1997; 155:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/87\">",
"      Tohda Y, Fujimura M, Taniguchi H, et al. Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin Exp Allergy 2002; 32:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/88\">",
"      Kanniess F, Richter K, Janicki S, et al. Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma. Eur Respir J 2002; 20:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/89\">",
"      Ilowite J, Webb R, Friedman B, et al. Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Ann Allergy Asthma Immunol 2004; 92:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/90\">",
"      Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 2003; 327:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/91\">",
"      Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/92\">",
"      Ringdal N, Eliraz A, Pruzinec R, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003; 97:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/93\">",
"      Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2011; :CD003137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/94\">",
"      Busse W, Nelson H, Wolfe J, et al. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999; 103:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/95\">",
"      Terashima T, Amakawa K, Matsumaru A, Yamaguchi K. Correlation between cysteinyl leukotriene release from leukocytes and clinical response to a leukotriene inhibitor. Chest 2002; 122:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/96\">",
"      Asano K, Shiomi T, Hasegawa N, et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/97\">",
"      Dahl&eacute;n SE, Malmstr&ouml;m K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/98\">",
"      Rabinovitch N, Graber NJ, Chinchilli VM, et al. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. J Allergy Clin Immunol 2010; 126:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/99\">",
"      Tanaka H, Saito T, Kurokawa K, et al. Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG)F1alpha. Allergy 1999; 54:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/100\">",
"      Cai C, Yang J, Hu S, et al. Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma. Lung 2007; 185:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/101\">",
"      Drazen JM, Yandava CN, Dub&eacute; L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/102\">",
"      Sampson AP, Siddiqui S, Buchanan D, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55 Suppl 2:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/103\">",
"      Currie GP, Lima JJ, Sylvester JE, et al. Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. Br J Clin Pharmacol 2003; 56:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/104\">",
"      Klotsman M, York TP, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/105\">",
"      Jiang Y, Borrelli LA, Kanaoka Y, et al. CysLT2 receptors interact with CysLT1 receptors and down-modulate cysteinyl leukotriene dependent mitogenic responses of mast cells. Blood 2007; 110:3263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/106\">",
"      Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009; 19:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/107\">",
"      Dahl&eacute;n B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/108\">",
"      Coreno A, Skowronski M, Kotaru C, McFadden ER Jr. Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma. J Allergy Clin Immunol 2000; 106:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/109\">",
"      Villaran C, O'Neill SJ, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol 1999; 104:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/110\">",
"      Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000; 132:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/111\">",
"      Coreno A, Skowronski M, West E, et al. Bronchoprotective effects of single doses of salmeterol combined with montelukast in thermally induced bronchospasm. Chest 2005; 127:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/112\">",
"      Pearlman DS, van Adelsberg J, Philip G, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol 2006; 97:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/113\">",
"      Bisgaard H, Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med 2003; 167:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/114\">",
"      Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/115\">",
"      Barnes N, Thomas M, Price D, Tate H. The national montelukast survey. J Allergy Clin Immunol 2005; 115:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/116\">",
"      Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/117\">",
"      Rundell KW, Spiering BA, Baumann JM, Evans TM. Bronchoconstriction provoked by exercise in a high-particulate-matter environment is attenuated by montelukast. Inhal Toxicol 2005; 17:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/118\">",
"      Gong H Jr, Linn WS, Terrell SL, et al. Anti-inflammatory and lung function effects of montelukast in asthmatic volunteers exposed to sulfur dioxide. Chest 2001; 119:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/119\">",
"      Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006; 117:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/120\">",
"      Kemp JP, Minkwitz MC, Bonuccelli CM, Warren MS. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma. Chest 1999; 115:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/121\">",
"      Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 2006; 100:1952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/122\">",
"      Camargo CA Jr, Weiss ST, Zhang S, et al. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999; 159:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/123\">",
"      Chen Y, Dales R, Krewski D, Breithaupt K. Increased effects of smoking and obesity on asthma among female Canadians: the National Population Health Survey, 1994-1995. Am J Epidemiol 1999; 150:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/124\">",
"      Young SY, Gunzenhauser JD, Malone KE, McTiernan A. Body mass index and asthma in the military population of the northwestern United States. Arch Intern Med 2001; 161:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/125\">",
"      Peters-Golden M, Swern A, Bird SS, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006; 27:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/126\">",
"      Mancuso P, Canetti C, Gottschalk A, et al. Leptin augments alveolar macrophage leukotriene synthesis by increasing phospholipase activity and enhancing group IVC iPLA2 (cPLA2gamma) protein expression. Am J Physiol Lung Cell Mol Physiol 2004; 287:L497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/127\">",
"      Fauler J, Fr&ouml;lich JC. Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest 1997; 27:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/128\">",
"      Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/129\">",
"      Kubavat AH, Khippal N, Tak S, et al. A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extended-release tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma. Am J Ther 2013; 20:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/130\">",
"      Berger W, De Chandt MT, Cairns CB. Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease. Int J Clin Pract 2007; 61:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/131\">",
"      Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001; 108:E48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/132\">",
"      Price DB, Swern A, Tozzi CA, et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006; 61:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/133\">",
"      Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001; 119:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/134\">",
"      Silverman RA, Nowak RM, Korenblat PE, et al. Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. Chest 2004; 126:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/1/30746/abstract/135\">",
"      Camargo CA Jr, Smithline HA, Malice MP, et al. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003; 167:528.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 553 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-6D749065E6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30746=[""].join("\n");
var outline_f30_1_30746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LEUKOTRIENE SYNTHESIS AND BIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cysteinyl leukotrienes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dihydroxy leukotrienes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Variations in leukotriene synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Leukotriene receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Receptors for cysLTs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Receptors for LTB4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LEUKOTRIENES IN ASTHMA PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Role of cysLTs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Role of LTB4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANTI-LEUKOTRIENE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Available agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL USE IN ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Use as first-line controller therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Compared to placebo",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Compared to inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - \"Real-world\" issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Additive benefit with inhaled GC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Compared to long-acting beta-agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Heterogeneity of response to controller therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Patient characteristics that predict responsiveness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Biomarkers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H720908755\">",
"      - Genotypic markers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Clinical characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Choice of anti-leukotriene agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Duration of therapeutic trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Use in acute asthma exacerbations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Use in asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/553\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/553|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/55/26495\" title=\"figure 1\">",
"      Leukotriene modifiers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/36/589\" title=\"figure 2\">",
"      LTE4 excretion in asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/62/13294\" title=\"figure 3\">",
"      LT inhibitors in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/553|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/12/20683\" title=\"table 1\">",
"      Usual doses antileukotriene",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/19/16698?source=related_link\">",
"      Beta agonists in asthma: Controversy regarding chronic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12789?source=related_link\">",
"      Enhancing patient adherence to asthma therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/50/13094?source=related_link\">",
"      Physiology of leptin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36278?source=related_link\">",
"      Severe asthma: Evidence for heterogeneity of the disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_1_30747="Etiologies of thunderclap headache";
var content_f30_1_30747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologies for thunderclap headache",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Subarachnoid hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sentinel headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral venous thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical artery dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spontaneous intracranial hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pituitary apoplexy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retroclival hematoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemic stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute hypertensive crisis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reversible cerebral vasoconstriction syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colloid cyst of the third ventricle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute complicated sinusitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary thunderclap headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections (eg, acute complicated sinusitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaplastic oligodendroglioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aqueductal stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vogt-Koyanagi-Harada syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30747=[""].join("\n");
var outline_f30_1_30747=null;
var title_f30_1_30748="Steroid medicines PI";
var content_f30_1_30748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some examples of steroid medicines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample US brand names",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Oral steroids",
"        </strong>",
"       </td>",
"       <td>",
"        Prednisone",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prednisolone",
"       </td>",
"       <td>",
"        Orapred&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methylprednisolone",
"       </td>",
"       <td>",
"        Medrol&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Inhaled steroids",
"        </strong>",
"       </td>",
"       <td>",
"        Fluticasone",
"       </td>",
"       <td>",
"        Flovent&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Budesonide",
"       </td>",
"       <td>",
"        Pulmicort Flexhaler&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mometasone",
"       </td>",
"       <td>",
"        Asmanex&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <strong>",
"         Topical steroids (creams, lotions, ointments, shampoos)",
"        </strong>",
"       </td>",
"       <td>",
"        Hydrocortisone",
"       </td>",
"       <td>",
"        Cortaid&reg;, Preparation H&reg; Hydrocortisone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triamcinolone",
"       </td>",
"       <td>",
"        Kenalog&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Betamethasone",
"       </td>",
"       <td>",
"        Diprolene&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Steroid eye drops",
"        </strong>",
"       </td>",
"       <td>",
"        Prednisolone",
"       </td>",
"       <td>",
"        Pred Forte&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Steroid ear drops",
"        </strong>",
"       </td>",
"       <td>",
"        Fluocinolone",
"       </td>",
"       <td>",
"        DermOtic&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Steroid nose sprays",
"        </strong>",
"       </td>",
"       <td>",
"        Fluticasone",
"       </td>",
"       <td>",
"        Flonase&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mometasone",
"       </td>",
"       <td>",
"        Nasonex&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Steroid injections for joints or spine",
"        </strong>",
"       </td>",
"       <td>",
"        Triamcinolone",
"       </td>",
"       <td>",
"        Aristospan&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Steroid injections in a vein (IV)",
"        </strong>",
"       </td>",
"       <td>",
"        Hydrocortisone",
"       </td>",
"       <td>",
"        Solu-Cortef&reg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methylprednisolone",
"       </td>",
"       <td>",
"        Solu-Medrol&reg;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table gives the names of some common steroid medicines. There are many others that are not listed here. If you want to know if your medicine is a steroid, ask your doctor, nurse, or pharmacist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30748=[""].join("\n");
var outline_f30_1_30748=null;
var title_f30_1_30749="Lovastatin in normal LDL";
var content_f30_1_30749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lovastatin reduces cardiac events in patients with near normal serum LDL cholesterol concentrations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 248px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the AFCAPS/TexCAPS trial 6605 men and women with near-normal serum LDL cholesterol concentrations (mean 150 mg/dL [3.9 mmol/L]) and no history of coronary heart disease were randomly assigned to lovastatin or placebo. Lovastatin reduced the composite primary endpoint (fatal or nonfatal myocardial infarction, sudden death, or unstable angina) by 37 percent (p&lt;0.001) compared with placebo. There was also a significant reduction in each of the individual endpoints when analyzed separately.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Downs, JR, Clearfield, M, Weis, S, et al for the AFCAPS/TexCAPS Research Group, JAMA 1998; 279:1615.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30749=[""].join("\n");
var outline_f30_1_30749=null;
var title_f30_1_30750="AP forearm";
var content_f30_1_30750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    AP view of normal forearm in 9-year-old",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 192px; height: 443px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior (AP) view of the forearm has minimal superimposition of the radial tuberosity (located at the proximal radius) over the proximal ulna and similar radiographic density for the proximal and distal forearm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30750=[""].join("\n");
var outline_f30_1_30750=null;
var title_f30_1_30751="Framingham ATPIII score men";
var content_f30_1_30751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64978%7ECARD%2F76742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64978%7ECARD%2F76742&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Framingham/ATP III point scores in men",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age, years",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        &nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20 to 34",
"       </td>",
"       <td>",
"        &nbsp;-9",
"       </td>",
"       <td colspan=\"4\" rowspan=\"10\">",
"        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35 to 39",
"       </td>",
"       <td>",
"        &nbsp;-4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40 to 44",
"       </td>",
"       <td>",
"        &nbsp;0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45 to 49",
"       </td>",
"       <td>",
"        &nbsp;3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 to 54",
"       </td>",
"       <td>",
"        &nbsp;6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55 to 59",
"       </td>",
"       <td>",
"        &nbsp;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60 to 64",
"       </td>",
"       <td>",
"        &nbsp;10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65 to 69",
"       </td>",
"       <td>",
"        &nbsp;11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70 to 74",
"       </td>",
"       <td>",
"        &nbsp;12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        75 to 79",
"       </td>",
"       <td>",
"        &nbsp;13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Total cholesterol mg/dL (mmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 20 to 39",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 40 to 49",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 50 to 59",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 60 to 69",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 70 to 79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;160 (3.4)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        160 to 199 (3.4 to 5.15)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 to 239 (5.17 to 6.18)",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        240 to 279 (6.2 to 7.21)",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;280 (7.24)",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 20 to 39",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 40 to 49",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 50 to 59",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 60 to 69",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 70 to 79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsmoker",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoker",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        HDL cholesterol mg/dL (mmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;60 (1.55)",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"       <td colspan=\"4\" rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 to 59 (1.29 to 1.53)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40 to 49 (1.03 to 1.27)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;40 (1.03)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\">",
"        Systolic blood pressure, mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Untreated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treated",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;120",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td colspan=\"4\" rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        120 to 129",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        130 to 139",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        140 to 159",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;160",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Point total",
"       </td>",
"       <td class=\"subtitle1\">",
"        10-year risk, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Point total",
"       </td>",
"       <td class=\"subtitle1\">",
"        10-year risk, percent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td colspan=\"2\" rowspan=\"9\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &ge;17",
"       </td>",
"       <td>",
"        &ge;30",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: These risk estimates for the development of coronary heart disease do not account for all important cardiovascular risk factors. Not included are diabetes mellitus (which is considered a CHD equivalent), family history of CHD, alcohol intake, and the serum C-reactive protein concentration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Adult Treatment Panel III at file://www.nhlbi.nih.gov/ The point total is determined in each category and the 10-year risk determined in the bottom row.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Framingham/ATP III point scores in women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age, years",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20 to 34",
"       </td>",
"       <td>",
"        -7",
"       </td>",
"       <td colspan=\"4\" rowspan=\"10\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35 to 39",
"       </td>",
"       <td>",
"        -3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40 to 44",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45 to 49",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 to 54",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55 to 59",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60 to 64",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65 to 69",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70 to 74",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        75 to 79",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Total cholesterol mg/dL (mmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 20 to 39",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 40 to 49",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 50 to 59",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 60 to 69",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 70 to 79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;160 (3.4)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        160 to 199 (3.4 to 5.15)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        200 to 239 (5.17 to 6.18)",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        240 to 279 (6.2 to 7.21)",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;280 (7.24)",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 20 to 39",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 40 to 49",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 50 to 59",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 60 to 69",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 70 to 79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsmoker",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smoker",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        HDL cholesterol mg/dL (mmol/L)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;60 (1.55)",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"       <td colspan=\"4\" rowspan=\"4\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 to 59 (1.29 to 1.53)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40 to 49 (1.03 to 1.27)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;40 (1.03)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\">",
"        Systolic blood pressure, mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Untreated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treated",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;120",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td colspan=\"3\" rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        120 to 129",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        130 to 139",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        140 to 159",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;160",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Point total",
"       </td>",
"       <td class=\"subtitle1\">",
"        10-year risk, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Point total",
"       </td>",
"       <td class=\"subtitle1\">",
"        10-year risk, percent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;9",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td colspan=\"2\" rowspan=\"9\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &ge;25",
"       </td>",
"       <td>",
"        &ge;30",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: These risk estimates for the development of coronary heart disease do not account for all important cardiovascular risk factors. Not included are diabetes mellitus (which is considered a CHD equivalent), family history of CHD, alcohol intake, and the serum C-reactive protein concentration. The point total is determined in each category and the 10-year risk determined in the bottom row.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Adult Treatment Panel III at file://www.nhlbi.nih.gov/.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_1_30751=[""].join("\n");
var outline_f30_1_30751=null;
